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Oesophageal cancer is diagnosed in more than 500,000 patients per year worldwide and with 
a 5-year survival of 15-25%, it is the sixth leading cause of cancer-related mortality1. There are 
two major histologic subtypes; squamous cell - and adenocarcinoma. Squamous cell carcinomas 
are predominantly located in the proximal oesophagus and most common in Asia, Africa and 
Southern America1. Risk factors are alcohol consumption and tobacco smoking2. In Europe, North 
America and Oceania adenocarcinoma of the distal oesophagus predominates3,4. Important risk 
factors for adenocarcinomas include obesity and gastro-oesophageal reflux disease5 and in many 
high-income countries adenocarcinoma rates has already surpassed or are predicted to surpass 
the incidence of squamous cell carcinomas6. Overall, oesophageal cancer rates are substantially 
higher in men than in women1.
Treatment historically consisted of surgery alone with a median overall survival of 2 years7. With the 
introduction of preoperative treatment strategies (e.g. chemotherapy, radiotherapy) the oncological 
outcomes improved8. In the Netherlands, neoadjuvant chemoradiotherapy (nCRT) followed by 
surgery is currently standard of care due to the higher survival rates and improved locoregional 
control as compared to surgery alone7,9.
The response to neoadjuvant treatment is currently determined at histopathology of the resection 
specimen after surgery10. It has been shown that with current chemoradiotherapy schemes, locally 
advanced tumours show a pathological complete response in 29% of the patients7. This has 
raised the question whether in this group of complete responders major resection surgery with 
high morbidity and risk for mortality is still justified11-13. An active surveillance strategy is not 
(yet) adopted as an alternative treatment but some retrospective cohort studies suggest noninferior 
oncological outcomes for active surveillance patients compared to standard surgical resection14-16. 
However, in patients staged as cCR treated with esophagectomy, in 18-55 per cent residual tumour 
was found in the resected tumour bed14-17.
Hence the current debate is whether organ preservation could be a safe alternative to surgery 
in patients with a clinical complete response to chemoradiotherapy. Critical is the selection and 
surveillance of the eligible patients. Three important questions need to be addressed: 1. Is there any 
residual disease in the irradiated tumour bed? 2. Are the lymph nodes sterilised? 3. Can we detect 
tumour regrowth at a curable stage during the active surveillance?
Current literature reports the accuracy of response evaluation after chemoradiotherapy using 
endoscopy18,19. Endoscopy provides information of only the luminal side of the tumour bed while 
residual disease is located beneath the mucosal wall layer in 28% of patients20,21. Therefore, 
endoscopic biopsies have a high number of false-negatives22. Endoscopic ultrasound (EUS) can 
more accurately visualise the deeper layers of the wall and differentiate visible lymph nodes. EUS 
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identifies 52% of complete responders based on a cut-off of residual wall thickness of 4.5 mm23. 
EUS combined with fine needle aspiration (EUS-FNA) detected 50% of patients with residual nodal 
disease after chemoradiotherapy24. Therefore, clinical assessment by endoscopy and EUS after 
chemoradiotherapy are insufficient to reliably select the patients for non-operative management. 
These shortcomings in clinical assessment warrant further investigation of imaging techniques to 
complement endoscopy and EUS.
Currently, FDG-PET/CT is part of the standard work up to rule out distant metastases and select 
patients eligible for preoperative chemoradiotherapy. Several studies support the use of FDG-PET/
CT to detect intermittent distant metastases after neoadjuvant chemoradiotherapy25-30. The role of 
FDG-PET/CT for the assessment of local tumour response after neoadjuvant chemoradiotherapy 
has so far been limited because the differentiation between residual tumour, fibrosis and radiation 
oesophagitis remains difficult27,31-34.
Advances in MRI technology have led to high resolution imaging of the oesophagus and proper 
visualisation of the oesophageal wall35-39. MRI also provides the opportunity to perform functional 
imaging such as diffusion-weighted MRI (DW-MRI). DW-MRI is used to determine the water 
diffusivity in tissue40,41. An increase of the cell density, secondary to cell proliferation in tumours, 
results in a high signal on diffusion-weighted images due to a decrease in diffusivity of extracellular 
water. From the DW-MRI apparent diffusion coefficient (ADC) maps can be generated, representing 
a quantitative measure of water diffusivity in tissue41. While malignancies with a high cellularity 
cause diffusion restriction, fibrosis does not. In rectal cancer active surveillance strategies, DW-MRI 
has proven its additional value to clinical assessment (digital rectal examination and endoscopy) 
of response to chemoradiotherapy42,43. MRI is also increasingly explored in studies focusing on 
response prediction of oesophageal cancer44.
We hypothesise that DW-MRI can improve the performance of clinical assessment of response to 
preoperative chemoradiotherapy and identifies patients with complete response who would be 
eligible for active surveillance.
The aim of this thesis is to explore the role of MRI for personalised treatment in locally advanced 
oesophageal cancer. 
The main study questions are:
- What is the diagnostic accuracy of clinical response evaluation on DW-MRI after 
chemoradiotherapy?
- What is the role for clinical response evaluation on DW-MRI in a multimodality diagnostic 
approach?
- Can DW-MRI be used for radiotherapy treatment planning?
CHAPTER 1
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Outline of this thesis
In Chapter 2 the visual response assessment on DW-MRI by three oncological specialised radiologists 
was explored. Chapter 3 evaluates the potential predictive value of quantitative diffusion-weighted 
MRI by performing a systematic review. Chapter 4 compares clinical response evaluation after 
nCRT on DW-MRI to FDG-PET/CT. Subsequently, Chapter 5 investigates the additional value of 
DW-MRI assessment to endoscopy and EUS. Lastly, Chapter 6 compares delineation variation 
on DW-MRI to currently used FDG-PET/CT to investigate the role of DW-MRI for radiotherapy 
treatment planning purposes.
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CHAPTER 2
ABSTRACT
Background
Patients with a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) 
for oesophageal cancer may benefit from non-surgical management. The aim of this study was to 
determine the diagnostic performance of visual response assessment of the primary tumour after 
nCRT on T2-weighted (T2W) and diffusion-weighted (DW) MRI.
Methods
Patients with locally advanced oesophageal cancer who underwent T2W- and DW-MRI (1.5T) 
before and after nCRT in two hospitals, between July 2013 and September 2017, were included in 
this prospective study. Three radiologists evaluated T2W images retrospectively using a five-point 
score for the assessment of residual tumour in a blinded manner and immediately rescored after 
adding DW-MRI. Histopathology of the resection specimen was used as the reference standard; 
ypT0 represented a pCR. Sensitivity, specificity, area under the receiver operating characteristic 
(ROC) curve (AUC) and interobserver agreement were calculated.
Results
Twelve of 51 patients (24 per cent) had a pCR. The sensitivity and specificity of T2W-MRI for 
detection of residual tumour ranged from 90 to 100 and 8 to 25 per cent respectively. Respective 
values for T2W+DW-MRI were 90–97 and 42–50 per cent. AUCs for the three readers were 0.65, 
0.66 and 0.68 on T2W-MRI, and 0.71, 0.70 and 0.70 on T2W+DW-MRI (P =0.441, P =0.611 
and P =0.828 for readers 1, 2 and 3 respectively). The k value for interobserver agreement 
improved from 0.24–0.55 on T2W-MRI to 0.55–0.71 with DW-MRI.
Conclusion
Preoperative assessment of residual tumour on MRI after nCRT for oesophageal cancer is feasible 
with high sensitivity, reflecting a low chance of missing residual tumour. However, the specificity 
was low; this results in overstaging of complete responders as having residual tumour and, 
consequently, overtreatment.
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INTRODUCTION 
A standard therapy with curative intent for patients with locally advanced oesophageal cancer 
consists of neoadjuvant chemoradiotherapy (nCRT) followed by surgery. nCRT improves survival 
compared with surgery alone (5-year survival rate 47 versus 33 per cent respectively)1. In 25–30 
per cent of patients with oesophageal cancer, the resection specimen shows no residual tumour 
cells (ypT0) after nCRT2,3, also known as a pathological complete response (pCR). Patients with 
a pCR have an excellent prognosis, with a 5-year recurrence-free survival rate of 62 per cent4,5, 
which is better than that of patients with vital tumour cells in the resection specimen (no pCR). 
The high postoperative morbidity and mortality rates after oesophagectomy raise the question 
of whether non-surgical management (watch and wait) is a safe alternative treatment option in 
patients with oesophageal cancer who have a clinical complete response (cCR)6.
To implement non-surgical treatment for advanced oesophageal cancer it is critical to accurately 
identify pCR. CT and fluorodeoxyglucose (FDG) PET/CT are both inaccurate in discriminating 
residual disease from pCR owing to the presence of wall thickening and/or radiation oesophagitis7-13. 
The same is true for endoscopic ultrasonography (EUS), which has an accuracy of only 36 per cent 
for ypT determination14,15. Endoscopic response evaluation after nCRT is hampered by the fact that 
it provides information only on the luminal side of the oesophagus16, whereas residual cancer cells 
are located beneath the mucosal layer in a subset of patients17,18. Even deeper bite-on-bite biopsies 
combined with EUS and fine-needle aspiration of suspicious lymph nodes yielded a negative 
predictive value (NPV) of only 45 per cent for detecting tumours with a tumour regression grade 
(TRG) of 2 or higher11. Previous retrospective cohort studies19-22 reported on patients with a cCR 
after neoadjuvant treatment who did not have surgery but underwent serial response assessments 
including endoscopy, EUS, CT and/or FDG-PET/CT. Among those assessed as having a cCR who 
did undergo oesophagectomy, residual tumour was found in 28–33 per cent of patients19-21. In a 
propensity-based matching study22, after a median follow-up of 51.1 months, local recurrence had 
developed more frequently among patients with a cCR who underwent a watch-and-wait approach 
than in those who had surgical treatment.
The limitations of the current response assessment tools warrant investigation of other imaging 
techniques. In rectal cancer, MRI can aid in the diagnosis of a cCR after nCRT23,24. Although MRI of 
the oesophagus is technically more challenging, owing to oesophageal motility and motion of the 
surrounding heart and diaphragm, advances in technology now enable the acquisition of high-
resolution magnetic resonance (MR) images. Previous studies25-29 on response prediction with MRI 
in oesophageal cancer focused on quantitative diffusion-weighted (DW) MRI parameters. However, 
visual response assessment on T2-weighted (T2W) and functional DW-MRI in rectal cancer yielded 
higher sensitivity for detecting residual tumour compared with quantitative assessment30. The 
performance of visual response assessment on MRI in oesophageal cancer is as yet unknown. The 
aim of this study was to determine the diagnostic performance of visual response assessment of the 
18
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primary oesophageal tumour after nCRT on T2W-MRI and functional DW-MRI.
METHODS
Patients diagnosed with locally advanced oesophageal cancer were enrolled prospectively and data 
were analysed retrospectively. The study was approved by the local medical ethics committees and 
registered at ClinicalTrials.gov (NCT02139488 and NCT02125448). Written informed consent to 
participate was obtained from the patients. Patients underwent MRI before and after nCRT between 
July 2013 and September 2017. Inclusion criteria were: biopsy-proven locally advanced, non-
metastatic oesophageal cancer; 5 weeks of nCRT (total of 41.4 Gy in 23 fractions, with weekly 
administration of carboplatin and paclitaxel) followed by oesophagectomy; and maximum of 21 
days between preoperative MRI and surgery. Patients were excluded if MRI quality was judged 
insufficient by at least two radiologists. Causes of insufficient image quality were severe motion 
artefacts leading to blurred T2W images, and lack of, or only slight, diffusion restriction in the 
spleen as a surrogate marker of inadequate DWimages.
Image acquisition
Imaging was performed on a 1.5-T MRI scanner (Achieva or Ingenia; Koninklijke Philips, Best, 
the Netherlands), using Torso-XL (16 channel) or anterior/posterior (28 channel) receiver coils 
respectively (supplied by Koninklijke Philips). The MRI protocol consisted of T2W multislice turbo 
spin-echo sequences in transverse (slice thickness 4 mm) and sagittal (slice thickness 3 mm) planes. 
A respiratory navigator was positioned on the diaphragm, and to reduce motion artefacts, images 
were acquired only during expiration31. A DW echo-planar imaging sequence was acquired in 
the transverse direction with b=0, b=200 and b=800 s/mm2, and a slice thickness of 4 mm. 
The transverse T2W and DW sequences were angled in identical planes. Detailed MRI sequence 
parameters are provided in Table S1 (supporting information).
Image evaluation
Images were analysed independently by three expert radiologists, who were blinded to tumour 
characteristics (location, histology, TNM stage32) and clinical outcomes. The radiologists first judged 
images of the primary tumour area acquired by T2W-MRI and DW-MRI before nCRT. They then 
scored the images obtained by T2W-MRI after nCRT for the likelihood of residual tumour. Finally, 
still in the same reading session, DW-MR images of b=800 s/mm2 were added and the scoring 
was repeated. A five-point confidence level score (CLS) was used, derived from previous studies in 
rectal cancer (CLS1, definitely complete response; 2, probably complete response; 3, inconclusive; 
4, probably residual tumour; 5, definitely residual tumour)23.
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MRI criteria
A complete response of the primary tumour on T2W-MRI was defined by a normalized oesophageal 
wall or only a thin hypointense signal (indicating fibrosis) without distortion of the wall; on DW-MRI, 
a complete response of the primary tumour was defined by the absence of high signal on images 
of b=800 s/mm2 in the irradiated tumour bed. On T2W-MRI, a residual mass with persistent 
isointense signal or the presence of mixed hyperintense and hypointense signals within the tumour 
bed were considered signs of residual tumour; on DW-MRI, the presence of high signal within the 
tumour bed indicated residual tumour. These criteria are illustrated in Figs 1 and 2.
Figure 1. MRI of a patient with locally advanced oesophageal cancer that showed a pathological 
complete response to neoadjuvant chemoradiotherapy
Images from a 55-year-old man with a cT3N0 lower oesophageal squamous cell carcinoma, and a 
complete pathological response after neoadjuvant chemoradiotherapy (nCRT) and oesophagectomy 
(tumour regression grade 1, ypT0 N0). a–c: T2-weighted (T2W) sagittal (a) and transverse (b) 
images before chemoradiotherapy show a hyperintense oesophageal wall, accompanied by a 
hyperintense signal on diffusion-weighted (DW) imaging (c). d–f: T2W sagittal (d) and transverse 
(e) images after nCRT show a hypointense oesophageal wall, indicating fibrosis; no high signal 
remained on the corresponding DW image (f). Arrows mark (initial) tumour location.
a. T2W sagittal image
before nCRT
b. T2W transverse image
before nCRT
c. DW image before nCRT
d. T2W sagittal image
after nCRT
e. T2W transverse image
after nCRT
f. DW image after nCRT
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Figure 2. MRI of a patient with locally advanced oesophageal cancer that showed pathological 
residual tumour after chemoradiotherapy and surgery
Images from a 78-year-old man with a cT2 N0 lower oesophageal adenocarcinoma, who had 
residual tumour after neoadjuvant chemoradiotherapy (nCRT) and oesophagectomy (tumour 
regression grade 5, ypT2 N0). T2-weighted (T2W) sagittal (a,d) and transverse (b,e) images before 
(a,b) and after (d,e) nCRT both show a hyperintense oesophageal wall. The corresponding b=800 
diffusion-weighted (DW) images before (c) and after (f) nCRT demonstrate a clear hyperintense 
signal, highly suspicious for tumour. Arrows mark tumour location.
Reference standard
Histopathological examination of the resection specimen was performed by dedicated gastrointestinal 
pathologists at the two centres. The resection specimen was evaluated in accordance with the 
seventh edition of the UICC protocol for ypTNM classification32. The TRG of the resected primary 
tumour was assessed according to Mandard and colleagues3. The tumour bed was embedded 
completely for histopathological analysis. A pCR was defined as ypT0 (TRG 1) and residual tumour 
as ypT1–4 (TRG 2–5).
a. T2W sagittal image
before nCRT
b. T2W transverse image
before nCRT
c. DW image before nCRT
d. T2W sagittal image
after nCRT
e. T2W transverse image
after nCRT
f. DW image after nCRT
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RESULTS 
Six of 57 patients were excluded: four had insufficient MRI quality, one patient had distant 
metastases after completion of nCRT and therefore did not undergo surgical resection, and one 
patient was deemed to have unresectable disease at surgical exploration. Therefore, 51 patients 
were evaluated (Fig. 3). Of the 51 included patients, 42 (82 per cent) were diagnosed with 
adenocarcinoma and nine (18 per cent) with squamous cell carcinoma. Table 1 shows baseline 
patient and tumour characteristics at both institutes that participated in the study. Transhiatal 
oesophagectomy was performed in 24 patients (47 per cent) and transthoracic oesophagectomy 
in 27 (53 per cent), followed by gastric conduit reconstruction with cervical anastomosis in all 
patients. The median interval between the last radiation fraction and oesophagectomy was 59 
(range 24–75) days. It was 47 (17–65) days between the last radiation fraction and MRI, and 11 
(4–21) days from post-nCRT MRI until oesophagectomy. On histopathological assessment, a pCR 
of the primary tumour (ypT0, TRG 1) was found in 12 of 51 patients (24 per cent). In one of these 
patients, the disease was confirmed as ypT0N1, which was regarded a complete response of the 
primary tumour area (ypT0) in this study. The pCR rate was five of nine (56 per cent) for squamous 
cell carcinomas and seven of 42 (17 per cent) for adenocarcinomas. The remaining 39 patients 
had residual tumour, which was graded as TRG 2 in 17 of 51 patients (33 per cent), TRG 3 in 16 
(31 per cent), TRG 4 in four (8 per cent) and TRG 5 in two patients (4 per cent).
Excluded
     No oesophagectomy n=2
Patients with adequate images
n=53 (106 scans)
Excluded
     Insufficient T2W-MRI quality n=1
     Insufficient DW-MRI quality n=3
Patients who underwent MRI before and 
after nCRT n=57
Patients included for response assessment
n=51 (102 scans)
Figure 3. Study flow chart
nCRT, neoadjuvant chemoradiotherapy; T2W, T2-weighted; DW, diffusion-weighted.
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Table 1. Patient and tumour characteristics
Hospital 1 (n=32) Hospital 2 (n=19) Total (n=51)
Age (years)* 64 (53-72) 64 (60-68) 64 (56-72)
Sex ratio (M : F) 23 : 9 16 : 3 39 : 12
Tumour location
   Upper oesophageal
   Middle oesophageal
   Lower oesophageal
   Gastro-oesophageal junction
0
3
15
14
1
3
11
4
1 (2)
6 (12)
26 (51)
18 (35)
Histological tumour type
   Adenocarcinoma
   Squamous cell carcinoma
28
4
14
5
42 (82)
9 (18)
Grade of differentiation
  Well differentiated
   Moderately differentiated
   Poorly differentiated
   Undifferentiated
   Unknown
2
15
14
0
1
0
10
3
2
4
2 (4)
25 (49)
17 (33)
2 (4)
5 (10)
Clinical T category†
cT1
cT2
cT3
cT4a
1
8
23
0
0
4
14
1
1 (2)
12 (24)
37 (73)
1 (2)
Clinical N category†
cN0
cN1
cN2
cN3
15
6
9
2
4
8
7
0
19 (37)
14 (27)
16 (31)
2 (4)
Radicality of resection 
R0
R1
32
0
18
1 
50 (98)
1 (2)
Mandard grade 
TRG 1
TRG 2
TRG 3
TRG 4
TRG 5
6
10
12
3
1
6
7
4
1
1
12 (24)
17 (33)
16 (31)
4 (8)
2 (4)
Values in parentheses are percentages unless indicated otherwise; * values are median (i.q.r.).
† According to the seventh edition of the TNM classification32.
Hospital 1, Netherlands Cancer Institute; Hospital 2, University Medical Center Utrecht. TRG, tumour regression grade.
Diagnostic performance
ROC curves for the assessment of residual tumour after nCRT are shown in Fig. 4. AUCs on T2W-
MRI were 0.65 for reader 1, 0.66 for reader 2 and 0.68 for reader 3. After addition of DW-MRI, 
AUCs were 0.71, 0.70 and 0.70 respectively (P =0.441, P =0.611 and P =0.828). The sensitivity 
for detection of residual tumour ranged from 90 to 100 per cent on T2W-MRI alone, and from 90 
to 97 per cent after addition of DW-MRI. Specificity ranged from 8 to 25 per cent on T2W-MRI 
alone, and from 42 to 50 per cent after addition of DW-MRI (Table 2). The numbers of MRI-positive 
and -negative tests per TRG stage for response assessment on T2W+DW-MRI are shown in Table 3.
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Figure 4. Receiver operating characteristic curves for assessment of residual tumour after 
neoadjuvant chemoradiotherapy using T2-weighted MRI and T2-weighted combined with diffusion-
weighted MRI.
a reader 1, b reader 2 and c reader 3. T2W, T2-weighted; DW, diffusion-weighted.
Comparison of areas under the curve for T2W-MRI versus T2W+DW-MRI:
a P =0.441, b P =0.611, c P =0.828 (DeLong test33).
Table 2. Diagnostic performance for assessment of residual tumour
T2W-MRI T2W+DW-MRI
Reader 1 Reader 2 Reader 3 Reader 1 Reader 2 Reader 3
Sensitivity (%) 100
(89, 100)
90
(75, 97)
90
(75, 97)
95
(81, 99)
97
(85, 100)
90
(75, 97)
Specificity (%) 8
(0, 40)
25
(7, 57)
25
(7, 57)
50
(22, 78)
42
(17, 71)
42
(17, 71)
PPV (%) 78
(64, 88)
80
(64, 90)
80
(64, 90)
86
(71, 94)
84
(70, 93)
83
(68, 92)
NPV (%) 100
(6, 100)
43
(12, 80)
43
(12, 80)
75
(36, 96)
83
(37, 99)
56
(23, 85)
True-positive 39 35 35 37 38 35
False-positive 11 9 9 6 7 7
True-negative 1 3 3 6 5 5
False-negative 0 4 4 2 1 4
Accuracy (%) 78 75 75 84 84 78
AUC* 0.65
(0.47, 0.83)
0.66
(0.49, 0.83)
0.68
(0.51, 0.86)
0.71
(0.52, 0.90)
0.70
(0.52, 0.88)
0.70
(0.51, 0.88)
Values in parentheses are 95 per cent confidence intervals. Residual tumour (tumour regression grade 2–5 in resected 
primary tumour) was considered the positive outcome.
T2W, T2-weighted; DW, diffusion-weighted; PPV, positive predictive value; NPV, negative predictive value; AUC, area 
under the receiver operating characteristic curve.
*Comparison of T2W-MRI versus T2W+DW-MRI: P =0.441, P =0.611 and P =0.828 for readers 1, 2 and 3 
respectively (DeLong test33).
a. Radiologist 1 b. Radiologist 2 c. Radiologist 3
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Equivocal (confidence level 3) scores
Readers 1, 2 and 3 assigned 16, 30 and 15 equivocal scores (CLS3) respectively on T2W-MRI, 
which decreased to 9, 11 and 9 equivocal scores after the addition of DW-MRI. Fig. 5 shows an 
example of a tumour for which all readers assigned an equivocal score on T2W-MRI, whereas a 
correct diagnosis of residual tumour (CLS4 for all 3 readers) was made after addition of DW-MRI.
Interobserver agreement
Interobserver agreement was fair to moderate on T2WMRI alone (quadratic weighted k =0.24, 
0.55 and 0.41), and increased to moderate to good on T2W+DW-MRI (quadratic weighted k 
=0.55, 0.71 and 0.61).
Table 3. Number of test-positive and test-negative patients according to tumour regression grade 
for response assessment on T2-weighted combined with diffusion-weighted MRI
Number of patients
Mandard 
grade
Reader 1 Reader 2 Reader 3
MRI-positive MRI-negative MRI-positive MRI-negative MRI-positive MRI-negative
TRG 1 6 6 7 5 7 5
TRG 2 16 1 16 1 15 2
TRG 3 15 1 16 0 14 2
TRG 4 4 0 4 0 4 0
TRG 5 2 0 2 0 2 0
TRG, tumour regression grade according to Mandard and colleagues3;
MRI-positive, clinical residual tumour; MRI-negative, clinical complete response.
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Figure 5. MRI of a patient with locally advanced oesophageal cancer located at the gastro-
oesophageal junction
Images from an 80-year-old man with a cT3 N0 squamous cell carcinoma located at the gastro-
oesophageal junction. Histopathology after oesophagectomy showed residual tumour (tumour 
regression grade 2, ypT1a N0). a–c T2-weighted (T2W) sagittal (a) and transverse (b) images 
before neoadjuvant chemoradiotherapy (nCRT) show a thick hyperintense wall, accompanied by a 
hyperintense signal on diffusion-weighted (DW) imaging (c). d–f After nCRT, the T2W images (d,e) 
show shrinkage of the wall with a mixed hyperintense and hypointense signal, which was assigned 
a confidence level score of 3 by all readers. The DW image (f) shows spots of hyperintense signal 
in the primary tumour area (arrow), which is suspicious for residual tumour and was therefore 
assigned a confidence level score of 4 by all readers. The area within the circle indicates normal 
stomach wall, which also shows small hyperintense areas on DWimaging. Arrows indicate tumour 
location.
a. T2W sagittal image
before nCRT
b. T2W transverse image
before nCRT
c. DW image before nCRT
d. T2W sagittal image
after nCRT
e. T2W transverse image
after nCRT
f. DW image after nCRT
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DISCUSSION
This study has shown that preoperative response assessment after nCRT for oesophageal cancer 
performed visually on (DW-)MRI has promising overall diagnostic performance, with AUCs in the 
range 0.65–0.71. The sensitivity of DW-MRI for detection of residual tumour was high (over 90 
per cent), indicating that the chance of missing residual tumour was small. Addition of images 
obtained by functional DW-MRI to the anatomical T2W-MRI protocol did not influence the overall 
diagnostic performance to a great extent, but had a positive impact on the specificity and NPV for 
most readers. Moreover, addition of DW sequences led to improved interobserver agreement and 
a reduction in the number of equivocal scores, indicating increased confidence of the readers. MRI 
showed promising visualization of the primary oesophageal tumour bed after nCRT in oesophageal 
cancer and could thereby improve current response assessment strategies. The main drawback was 
the poor specificity of MRI in this unimodal approach, which in clinical practice would result in 
overstaging of complete responders as having residual tumour and, consequently, overtreatment. 
Therefore, exploration of response assessment including MRI, but also other diagnostic modalities, 
after nCRT for locally advanced oesophageal cancer is warranted.
The present study evaluated oesophageal MRI for the assessment of complete response of the 
primary tumour by visual interpretation of morphology on T2W-MRI and restrictive signals on 
DW-MRI. Previous studies26,27,29 on this subject did not perform visual assessment, but focused on 
quantitative DW-MRI. These studies found that an increase in the apparent diffusion coefficient 
(ADC, a quantitative measure of the magnitude of diffusion) during nCRT, compared with before 
nCRT, is a predictor of response. Furthermore, an increase in ADC after nCRT compared with 
the baseline value seemed to be predictive of gross tumour response, defined as TRG 1–228,29 
or TRG 1–325. However, the results reported for the preoperative selection of complete response 
(TRG 1 only) using ADC values were poor26,29. In contrast, in the present study, preoperative 
visual response assessment on DW-MRI after nCRT had high sensitivity for the detection of residual 
tumour. Moreover, the cut-off was predefined and can therefore be used prospectively, whereas in 
the aforementioned studies exploring ADC values, the optimal cut-offs were defined retrospectively 
which limits their use.
A recent study11 of clinical assessment with endoscopy/EUS, in which bite-on-bite biopsies and 
fine-needle aspirates were obtained after nCRT, yielded a specificity of 72 per cent for detection 
of residual tumour, which is higher than the specificity in the present study. However, the reported 
sensitivity of 77 per cent was lower than values of over 90 per cent in the present study. Combined 
with clinical examination and endoscopy, (DW-)MRI has led to the safe selection of patients with 
rectal tumours for a watch-and-wait policy after nCRT35. Combining (DW-)MRI and endoscopy/
EUS will potentially result in accurate assessment of pCR after nCRT for oesophageal cancer without 
missing residual disease.
The specificity for detection of residual tumour improved from 8–25 to 42–50 per cent after adding 
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DW-MRI in the present study. This specificity is, however, still low. One potential explanation for the 
overstaging of a pCR as residual tumour is the occurrence of small punctate foci of hyperintensity 
at the former tumour bed on images obtained with b=800 DW-MRI (implying restricted diffusion, 
which raises the suspicion of tumour). These false-positive foci were observed in patients with a 
tumour of the gastro-oesophageal junction and may be explained by the fact that the normal 
stomach wall also shows small hyperintensities on DW-MRI, or by the presence of radiation-
induced inflammation. Prolonging the interval between the end of radiotherapy and MRI may result 
in resolution of inflammation. Furthermore, prolonging the interval between radiation and surgery 
may lead to an increase in pCR rates. A recent analysis in oesophageal cancer36 showed that a 
longer interval between nCRT and surgery increased pCR rates, without increasing the frequency 
of postoperative complications.
This study had a relatively large sample size compared with previous response studies in 
oesophageal cancer; however, validation in a larger cohort is required. This will also allow 
subgroup analyses of squamous cell carcinoma and adenocarcinoma. Another potential limitation 
is that ADC maps were not included in the response evaluation, although the readers could always 
refer to the T2W images to rule out, for example, shine-through effects caused by fluid in the 
oesophageal lumen. Furthermore, lymph node response was not assessed for two reasons. The 
differentiation between benign and malignant lymph nodes on oesophageal T2W-MRI remains 
challenging as non-enlarged nodes may harbour malignant cells, whereas reactive (benign) nodes 
may be enlarged37,38. DW-MRI can detect lymph nodes, but all lymph nodes have a high signal on 
DW images. In patients with T0N1 rectal cancer, MRI showed poor performance for detection of 
lymphadenopathy39. Second, the field of view (FOV) of MRI in this study focused on the primary 
tumour and did not comprise the complete craniocaudal perioesophageal area owing to imaging 
time restrictions. Hence, lymph nodes outside this FOV could not be assessed. Therefore, this 
study focused on tumour detection at the primary tumour bed only (TRG 1, ypT0). Other response 
assessment tools are needed for the detection of lymph node metastases after nCRT, such as EUS.
To overcome the limitations of the present study and further increase specificity without decreasing 
sensitivity for the preoperative detection of residual tumour in oesophageal cancer, larger studies 
are needed. The multicentre observational PRIDE (Preoperative Image-guided Identification of 
Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer) study40 was initiated to 
explore the combination of multiple diagnostic modalities in assessing the response of the primary 
tumour and lymph nodes to chemoradiotherapy. This study aims to develop an optimal multimodal 
response prediction model focusing on clinical (endoscopy and EUS) and radiological (MRI and 
FDG-PET/CT) assessment combined with patient-specific parameters (such as circulating tumour 
DNA) for oesophageal cancer.
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ABSTRACT
Purpose
The aim was to perform a systematic review on the value of diffusion-weighted MRI (DW-MRI) 
with apparent diffusion coefficient (ADC) mapping in the prediction and assessment of response to 
chemo- and/or radiotherapy in oesophageal cancer.
Materials and methods
A systematic search was performed on Pubmed, Embase, Medline and Cochrane databases. 
Studies that evaluated the ADC for response evaluation before, during or after chemo- and/or 
radiotherapy were included. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 
was used to assess the quality of the included studies.
Results
Fourteen studies, comprising 516 patients, in which the response to treatment in oesophageal 
cancer was evaluated on ADC maps were included. Acquisition parameter settings for DW-
MRI and ROI placement varied substantially. The reference standard was RECIST or endoscopic 
assessment in eight non-surgery studies and histopathology after surgery in six studies. A high pre-
treatment ADC significantly correlated with good response in three out of 12 studies; conversely, 
one study reported a significantly higher pre-treatment ADC in poor responders. In five out of eight 
studies good responders showed a significantly larger relative increase in ADC two weeks after the 
onset of treatment (range 23–59%) than poor responders (range 1.5–17%). After chemo- and/or 
radiotherapy ADC results varied considerably, amongst others due to large variation in the interval 
between completion of therapy and DW-MRI.
Conclusion
DW-MRI for response evaluation to chemo- and/or radiotherapy in oesophageal cancer shows 
variable methods and results. A large relative ADC increase after two weeks of treatment seems 
most predictive for good response.
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INTRODUCTION
Oesophageal cancer is a malignancy with a poor prognosis, as reflected by an average overall 
5-year survival of only 18%1. Locally advanced oesophageal cancer patients are generally treated 
by chemo- and/or radiotherapy, either as definite treatment or as neoadjuvant treatment prior to 
surgery2-4. However, not all patients benefit equally. In 23% of adenocarcinomas (AC) and 49% 
of squamous cell carcinomas (SCC) a pathological complete response (pCR, tumour regression 
grade (TRG) 1) is determined on histopathology of the resection specimen after neoadjuvant 
chemoradiotherapy (nCRT)2,5. On the other hand, after nCRT and surgery 18% of patients have 
TRG 4 or 5, meaning >50% vital residual tumour cells in the primary tumour bed2,5.
Accurate early prediction of poor response to chemo- and/or radiotherapy using imaging 
techniques could allow for early adjustments in a patient’s treatment plan. Thereby, unnecessary 
toxicity of the chemo- and/or radiotherapy can potentially be avoided6. Some studies on 18F 
fluorodeoxyglucose positron emission tomography (FDG-PET/CT) have shown that tumours in 
non-responders demonstrate a smaller change in maximum standardized uptake value (SUVmax) 
compared to responders after 14 days of nCRT7,8. However, the optimal threshold SUVmax value for 
prediction is still uncertain and varies between the studies, which limits its clinical applicability9-11. 
Another study showed that the standardized uptake ratio (SUR) was associated with overall 
survival, whereas this parameter was not associated with locoregional tumour control12.
In the group of patients who respond well to chemo- and/or radiotherapy the complete responders 
may benefit from a nonsurgical approach. These patients have a significantly improved long-term 
survival compared to patients with residual tumour3,13,14. In order to assess a clinical complete 
response (cCR) after neoadjuvant treatment, endoscopy and endoscopic ultrasound (EUS) are 
currently being examined13-17. However, previous studies report false negative results (cCR in TRG 
2–5 tumours) in 28–45%13,15-17. The predictive value of FDG-PET/CT after CRT is lower compared 
with its value during CRT, potentially due to radiation-induced inflammation that masks the actual 
disappearance of tumour metabolic activity18,19. This encourages the exploration of the use of other 
imaging techniques.
In recent years, prediction and assessment of response using magnetic resonance imaging (MRI) 
and specifically diffusion-weighted MRI (DW-MRI) in oesophageal cancer has increasingly been 
explored. From the DW-MR images apparent diffusion coefficient (ADC) maps can be generated, 
representing a quantitative measure of water diffusivity in tissue20. The quantification of the ADC 
before, during and/or after (neoadjuvant) chemo- and/or radiotherapy potentially enables a more 
personalized treatment approach for locally advanced oesophageal cancer patients21.
The objective of this study was to systematically review the evidence for the use of the ADC values 
in locally advanced oesophageal cancer response prediction and assessment to (neoadjuvant) 
chemo- and/or radiotherapy.
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METHODS
Literature search
A systematic literature search was performed in the Pubmed, Embase and the Cochrane Library 
electronic databases from January 2000 until February 2019. The following search terms were used 
(including synonyms and related words): ‘oesophageal cancer’, ‘magnetic resonance imaging’, 
‘treatment response’. The full search strategy can be found in the electronic supplementary 
material (Supp. Table 1). The literature search and study selection were independently performed 
by two reviewers (SV and AB). Any discrepancies were resolved through a consensus discussion 
afterwards. Reviews and conference contributions were excluded.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) studies including patients with histologically confirmed 
diagnosis of oesophageal cancer, (2) patients underwent DW-MRI, (3) ADC used for response 
prediction or evaluation, (4) the reference standard comprises tumour response to therapy: either 
assessed at histopathology after esophagectomy, or measured by the Response Evaluation Criteria 
in Solid Tumours (RECIST) on follow-up scanning in patients who did not undergo surgery22,23. In 
case of overlapping study populations, the study with the largest study population was included.
Identification of eligible studies
The literature search yielded a total of 1337 papers after removal of duplicates. Based on title 
1185 articles were excluded, because they were not relevant to the study question. 119 articles 
were excluded after reading the abstract, because they either did not focus on oesophageal cancer 
and/or DW-MRI. The remaining 33 papers were studied in full text. Of these, 19 studies were 
excluded19-44. The reasons for exclusion are outlined in Fig. 1. Eventually 14 studies were included. 
Literature selection results are displayed in accordance with the preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) guidelines in Fig. 124.
Data extraction and quality assessment
Fourteen relevant papers were included. Selected studies were evaluated for methodological quality 
using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2 criteria)25. A meta-
analysis was not performed because of the heterogeneity of the studies. Information of the MRI field 
strength, the chosen b-values and definition of the region of interest (ROI) was extracted per study. 
The treatment characteristics were classified as neoadjuvant chemotherapy (nCTx), neoadjuvant 
chemoradiotherapy (nCRT), definitive radiotherapy (dRT) or definitive chemoradiotherapy (dCRT). 
Furthermore, data on the evaluation of response before, during and after treatment including 
diagnostic performance and ADC values were extracted.
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Exclusion based on abstracts
n=119
Titles screened
n=1337
Abstracts screened
n=152
Full-text articles assessed for eligibility
n=33
Studies included in systematic review
n=14
Exclusion based on titles
n=1185
Exclusion based on full text, n=19
n=4 no chemo- and/or radiotherapy26-29
n=3 no differentiation responders vs. poor responders30-32
n=2 ADC in normal vs. tumor tissue33,34
n=1 overlap of inclusion period with other study35
n=1 pathologic features as reference standard36
n=1 survival as reference standard37
n=1 DW-MRI vs. FDG-PET/CT38
n=1 inter/intra observer reproducibility39
n=1 treated as gastric cancer40
n=1 multimodal response assessment vs. RECIST41
n=1 correlated ADC values with pathology of biopsy42
n=1 focus on predicting resectability43
n=1 focus on qualitative response assessment44
Citations identified through 
database searching
n=1659
Additional citations identified 
through reference checking
n=0
Citations after duplicates removed
n=1337
FIgure 1. PRISMA flowchart describing the identification and inclusion of the studies
RESULTS
General study characteristics
Fourteen studies, published between 2011 and 2018, included a total of 516 patients (356 SCC, 
96 AC, 2 adenosquamous carcinoma, 62 unknown histology) and measured the ADC to evaluate 
response. The basic characteristics regarding field strength, MRI acquisition parameter settings for 
diffusion weighting and ROI placement are shown in Table 1. MRI scans were performed on a field 
strength of 1.5 Tesla in nine studies45-53. 3.0 Tesla MRI scanners were used in four studies54-57. One 
study did not report on the field strength used58. Furthermore, 12 out of 14 studies delineated the 
ROI on DWI and b-values used to calculate the ADC varied between b = 0 and b = 1000 (Table 1).
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Table 1. Field strength, MRI acquisition parameter settings for diffusion weighting and ROI 
placement
b-values (s/mm2);
field strength MRI
Delineation of 
ROI on
Excluded from 
ROI
Definition of 
ROI in case 
of complete 
remission
ROI adjusted 
per time point
Reference standard = RECIST
Aoyagi, 
201145
b=0, 1000;
1.5 T
DWI NR n.a.* n.a.*
Imanishi, 
201347
b=0, 1000;
1.5 T
DWI NR NR Yes
Liu, 201654 b=0, 800;
3.0 T
DWI Vessels and 
necrotic areas
n.a.* n.a.*
Wang, 
201658
b=0, 600;
T NR
DWI NR DWI based 
volume recorded 
as 0
Yes
Kozumi, 
201856
b=50, 800;
3.0 T
DWI Lumen n.a.* n.a.*
Li, 201852 b=0, 10, 20, 30, 50, 
80, 100, 150, 200, 
400, 600, 800; 1.5 T
DWI Necrosis, air and 
vessels
ROIs at initial 
tumour location
Yes
Zheng, 
201857
b=0, 25, 50, 75, 
100, 150, 200, 500, 
800; 3.0 T
DWI Necrosis, cystic 
degeneration, 
adjacent tissues
3 identical ROIs 
at initial tumour 
location
Yes
Guo, 
201850 †
B=0, 600, 800, 
1000; 1.5 T
DWI NR NR NR
Reference standard = Histopathology
De Cobelli, 
201346
b=0, 600;
1.5 T
T2-weighted 
MRI
Necrosis NR Yes
Weber, 
201348
b=50, 400, 800; 
1.5 T
MRI Necrosis NR Yes
Kwee, 
201449
b=0, 300, 1000; 
1.5 T
DWI NR NR Yes
Fang, 
201855
b=0, 200, 800; 3.0 T DWI Lumen (only 
in volume 
contouring; not in 
slice contouring)
NR Yes
Li, 201853 b=0, 700;
1.5 T
DWI Necrotic, 
cystic and 
haemorrhagic 
changes
ROI at initial 
tumour location
Yes
Heethuis, 
201851
b=0, 200, 800;
1.5 T
DWI NR NR Yes (only 
circumferen-
tial margins 
adjusted)
Abbreviations: ROI = region of interest; CRT = chemoradiotherapy; RECIST = Response Evaluation Criteria In Solid 
Tumours; NR = not reported; ADC = apparent diffusion coefficient.
* This study focused on MRI acquisition before the start of treatment only (therefore the ADC was measured on only one 
MRI scan).
† This study used clinical complete response on endoscopy as the reference standard.
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Quality of the included studies
The QUADAS-2 checklist results are shown in the electronic supplementary material (Supp. Fig. 
1)25. The risk of bias regarding patient selection was high in one study, which only included cT4 
tumours47. Patient selection was scored unclear if an inclusion period and inclusion number were 
reported without explaining potential exclusions from analyses25,50,54-56.
One study did not report the reference standard. Therefore, the study applicability was scored 
‘unclear’54. However, in this study none of the patients underwent surgery thus response was 
probably determined on imaging after treatment. Another study reported a clinical complete 
response on endoscopic assessment as the reference standard. This is not commonly used and was 
therefore scored as a high concern regarding applicability50.
Four studies had high risk of bias concerning flow and timing. These studies evaluated the treatment 
effect by RECIST on imaging immediately after completion of CRT47,50,52,58. This was considered bias 
because of the considerable chance of wall thickening due to radiation-induced esophagitis shortly 
after completion of (chemo-)radiotherapy. Another four studies were scored to have ‘unclear’ risk 
of bias concerning flow and timing. In two studies this was unclear because the interval between 
the end of treatment and the reference standard was not reported45,54. One study did not report on 
the interval between the MRI and surgery51. Lastly, in one study the treatment strategy was changed 
based on FDG-PET/CT scans obtained after 14 days48.
Prediction of response before treatment
Twelve studies evaluated pre-treatment ADC for the prediction of response after treatment, shown 
in Table 2 and in the electronic supplementary material (Supp. Fig. 2)45,47-50,52-58. A good response 
was determined in the histopathologic specimen, or using RECIST in patients who did not undergo 
surgery. Good response was either classified as complete response only or as complete and partial 
response together. The definition of a good response per study is displayed in Table 2.
Of the studies evaluating the pre-treatment ADC, three found a significantly higher pre-treatment 
mean ADC in patients with a good response compared to patients with a poor response45,48,58. 
Conversely, one study reported a significantly lower mean ADC in patients with complete and 
partial response (CR + PR, according to RECIST) versus patients with stable and progressive disease 
(SD + PD, according to RECIST)52. Furthermore, the use of percentiles (i.e. P25, P50, P75 and P90) 
of the pretreatment ADC to predict treatment outcome did not result in significant outcomes55,56.
In one study the pre-treatment ADC yielded an accuracy of 80% for predicting CR + PR (according 
to RECIST) using a cut-off value of 1.10 x 10-3 mm2/s 45. With a cut-off value of 1.74 x 10-3 mm2/s 
for mean ADC before treatment, the area under the curve (AUC) for predicting CR + PR was 
0.82 in another study52. A third study did not report a cut-off value but found that the mean ADC 
predicted pCR (TRG1) with an AUC of 0.8755.
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Prediction of response during treatment
Response prediction during treatment was reported in nine studies, summarized in Table 3 and 
in the electronic supplementary material (Supp. Fig. 3)47-52,55,57,58. Two studies found that complete 
responders determined with RECIST had a significantly higher ADC during treatment as compared 
to patients with PR, SD or PD57,58. Also, one study reported a significantly higher ADC during 
treatment in patients with clinical complete response on endoscopy compared to patients with 
residual tumour on endoscopy50. Imanishi et al. stated that the absolute ADC measured after 10 
fractions (20 Gray) of radiotherapy was significantly higher in CR + PR patients than in patients 
with SD + PD47. Contrarily, another study reported a significantly lower ADC during treatment for 
CR + PR patients as compared to SD + PD patients52.
Eight out of nine studies also reported on the relative increase in ADC measured during (per) 
treatment compared to pre-treatment ADC (%DADCper-pre)47-49,51,52,55,57,58. The findings are shown 
in Fig. 2. Five reported a significantly higher relative change in ADCper-pre in good versus poor 
responders47,51,52,55,57. In the aforementioned studies, the good responders had an ADC increase 
ranging from 23.5% to 58.7%, whereas poor responders had an ADC increase ranging from 
1.5% to 16.7%. Fang et al. even reported that the relative change of the mean ADC for the tumour 
volume predicted TRG1 with a perfect AUC of 1.0, using 28% as the cut-off55. Another study 
reported an AUC of 0.70 for predicting TRG1 + 2 using the 90th percentile of ADC, however, no 
cut-off value was reported51. Three out of eight studies did not find a difference in the ADC increase 
during treatment between good responders and poor responders48,49,58.
Assessment of response after treatment
The eight studies reporting on ADC values after treatment in the assessment of response to therapy 
are depicted in Table 4 and in the electronic supplementary material (Supp. Fig. 4)46,47,50-53,57,58. 
The ADC on DW-MRI acquired directly after dCRT was significantly higher in good responders 
compared to poor responders in three out of five studies reporting on the ADC at this time 
point47,50,58. Two recent studies did not confirm these results52,57. However, one of these did show 
a significantly higher ADC in good responders compared to poor responders one month after 
completion of CRT (p = 0.023)57. Seven out of eight studies reported on the relative ADC increase 
after (post) CRT compared to pre-treatment ADC (%DADCpost-pre)46,47,51-53,57,58. This is summarized 
in Table 4 and in Supp. Fig. 5. Three studies found significant differences in the relative ADC 
increase after treatment compared to before treatment for variable definitions of responder groups 
(77% in CR+PR versus 14.7% in PD+SD47; 171.3% in TRG1+2+3 versus -11.56% in TRG4+46; 
45% in TRG1+2 versus 23.1% in TRG3+ (90th percentile51)). Furthermore, one study reported a 
significant difference between TRG1+2 versus TRG3+ regarding the absolute ADC increase after 
treatment (increase of 1.22 x 10-3 mm2/s vs. 0.64 x 10-3 mm2/s, respectively, p = 0.00753). The 
remaining three studies did not find significant differences for the relative increase of ADC after 
treatment in good responders versus poor responders52,57,58.
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FIgure 2. Response prediction during treatment: relative difference in ADC before (pre) and during 
(per) treatment (%DADCper-pre) for good responders versus poor responders.
Abbreviations: RECIST = Response Evaluation Criteria In Solid Tumours23; ADC = apparent 
diffusion coefficient; CR = complete response according to RECIST; PR = partial response according 
to RECIST; Becker = histology according to the Becker score68; TRG = tumour regression grade 
according to Mandard5; SD = standard deviation; P90 = 90th Percentile.
The names represent first authors of included studies, followed by the definition of a good responder 
and the proportion of good responders in the particular study.
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DISCUSSION
This systematic review shows that response prediction and assessment with quantification of 
(changes in) ADC values on DW-MRI in oesophageal cancer patients is challenging. One of 
the greatest challenges in interpreting quantitative measurements is dealing with the practice 
variations regarding the image acquisition, e.g. the b-values applied to calculate the ADC, and 
the measurement technique, e.g. the ROI placement. The relative ADC change (%DADC) seems to 
be the most promising measure, with the advantage that relative measurements suffer less from 
practice variations compared to absolute (changes in) values.
The reviewed studies yield variable results in the absolute values and in both the sign and magnitude 
of the relative changes of ADC values which may be explained by the used techniques. Diffusion 
values measured with DWI and subsequent ADC mapping depend on the pulse sequence and 
post-processing methods used. With ADC mapping, typically one diffusivity value is assigned to 
all water present inside a voxel, whereas it is known that the microstructure of tissue is reflected 
in different diffusivity values for water molecules inside different compartments of the tissue59. For 
example, the diffusivity of intracellular water, extracellular water and that of water in the blood 
inside blood vessels will be different. On top of that, diffusion inside tissue may be anisotropic and 
randomly oriented capillary blood flow inside a voxel may influence the diffusion values measured. 
The influence of these effects on the measured diffusion values depends on sequence parameter 
settings, like the choice of b-values60,61. Therefore, the diffusivity derived from DWI at multiple 
b-values is called the apparent diffusion coefficient. For the included studies the chosen lowest 
b-value was b = 0 in most studies, and b = 50 in two studies45-58. The chosen highest b-value varied 
between b = 600 and b = 1000 among all included studies.
In addition, DWI scans are typically based on sequences employing an echo planar imaging (EPI) 
read-out. Such scans are prone to artefacts caused by field inhomogeneities, and to chemical shift 
artefacts caused by the presence of water and fat signals resonating at different frequencies62. 
With improper fat suppression, ADC values measured may be corrupted by the presence of fat. 
Another important cause of variation in ADC measurements is the ROI size and placement. Most 
studies, but not all, delineated the ROI on DWI (guided by anatomical sequences)45,47,49-58. This is 
regarded the most optimal method because of the geometrical distortion that may occur on EPI 
read-out based DWI62. A single ROI, multiple ROIs or volume of interest (VOI) were outlined on the 
DWI before start of the treatment and most studies adjusted the ROI(s)/VOI on the follow-up DWI46-
49,51-53,55,57,58. Also, some studies calculated mean ADC values whereas other reported median ADC 
values (or percentiles) which complicated the comparison between the studies.
Furthermore, in case of a good/complete response to treatment, studies generally did not outline 
how the investigators dealt with disappearance of the signal on DWI46-51,55. Only three studies stated 
that the ROI was delineated according to the apparent tumour bed52,53,57. The optimal placement of 
the ROI and how to deal with shrinkage of the oesophageal tumour, especially in case of a good or 
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even complete response to treatment, is still unknown. Theoretically, with an adjusted ROI per time 
point, the intrinsic signal within the residual suspect area is measured specifically, but the correct 
placement of the ROI in the most suspect areas is crucial in that case. Interobserver variability then 
becomes an issue. ROIs that over time include the complete original tumour area may also enable 
measurement of changes in the tissue that responded to the treatment, but this delineation is difficult 
due to shrinkage of the tumour and thereby thinning of the oesophageal wall.
Lastly, next to the above discussed variation in b-values and ROI placement, a potential technical 
explanation for variation in ADC measurements is the use of different field strengths: both 1.5 T 
and 3.0 T MR scanners were used. In this systematic review we observed no consistent differences 
between studies on 3.0 T versus 1.5 T MRI. Although a higher field strength has the advantage 
of an increased intrinsic signal-to-noise ratio, the diffusion-weighted imaging may suffer from 
increased magnetic susceptibility artefacts at air-tissue interfaces. For all the aforementioned 
technical reasons, efforts should be made to standardize DWI sequences and the methods used to 
calculate the ADC in order to achieve comparable results in MRI of the oesophagus.
The varying results of the included studies may also be explained by the intrinsic tumour 
characteristics. For example, ACs and SCCs have different response rates to chemoradiotherapy2. 
However, no specific differences in ADC values were observed between AC and SCC. In SCC 
tumours the pre-treatment ADC varied from 1.27 to 2.24 in complete responders and from 1.09 
to 1.83 in PR/SD/PD patients53,54,56-58. In studies including (mainly) AC pre-treatment ADC values 
varied from 1.17 to 2.22 in good responders and 1.03–2.62 in poor responders48,55. Also, a 
recent study on AC subtypes (according to the Laurén classification) showed that TRG 1/2 was 
found more often in intestinal (60%) compared to diffuse subtype oesophageal AC (24%)63. 
Furthermore, in rectal cancer MRI studies mucinous tumours are commonly excluded from analyses 
because they have high ADC values due to their low cellular density which introduces bias into 
the results64-66. The Laurén classification or mucinous tumour characteristics were unreported in the 
included studies, thus these intrinsic tumour effects could not be evaluated.
Although not all studies reached significance, the relative ADC increase after two weeks of 
treatment showed a trend towards a larger increase of ADC in good responders compared to 
poor responders47-49,51,52,55,57,58. This is probably due to the early effect of (chemo-)radiotherapy 
on the tumour microenvironment inducing tumour necrosis, with a loss of cell membrane integrity 
and an increase of the extracellular space, typically resulting in an increase of the ADC. However, 
the magnitude of the relative ADC increase during treatment and thereby the cut-off between 
complete and incomplete responders differed per study (14–29%). These differences in relative 
ADC increase may be (partially) explained by the definition of a complete response, since some 
studies not only discriminate complete responders but also include near-complete responders in 
the good responder group. Furthermore, the studies in patients undergoing definitive chemo- and/
or radiotherapy did not have histopathology as the reference standard but instead used RECIST 
criteria (or endoscopic assessment in one case50). RECIST criteria are difficult to use in oesophageal 
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tumours as following RECIST guidelines tumour diameters can only be measured in the axial planes, 
while oesophageal tumours mostly grow longitudinally along the oesophageal wall, which can be 
better measured in the sagittal or coronal plane23,67. Also, wall thickening often remains present 
after chemoradiotherapy due to radiation esophagitis, even in the absence of residual tumour.
Results on the relative increase in ADC after treatment (%D ADCpost) instead of during treatment 
varied more substantially between the studies, which may only for a small part be explained by 
differences regarding the definition of complete response. Notably, the time-point of ADCpost 
measurements varied from a few days up to 9 weeks after treatment. The presence of radiation 
induced inflammation effects shortly after completion of (chemo-)radiotherapy is likely to influence 
ADC measurements early after treatment. Also, as stated before, ROI size and placement for ADC 
measurements after treatment is hampered by small or absent tumour after treatment in case of a 
good response. Therefore, measurements of ADC for quantitative analyses may be useful before 
and during CRT, whereas response after CRT may likely rather be assessed visually as was shown 
in a recent study44. However, the addition of endoscopy, EUS and FDG-PET/CT to the visual MRI 
assessment may be important in order to select complete responders for organ preservation.
In general, the studies included in this systematic review suggest that ADC measurements on 
DW-MRI have potential for prediction of response to treatment in oesophageal cancer patients, 
especially the relative increase in ADC two weeks after the onset of treatment seems promising. 
However, specific ADC cut-off values considerably differed between studies and therefore cannot 
(yet) be applied in clinical practice on individual patients. Efforts should be made to standardize 
DWI sequences and the methods used to calculate the ADC in order to achieve comparable results.
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SUPPLEMENTARY FILES
Suppl. Table 1. Literature search performed on February 27th, 2019
Search term Results
1. exp esophageal cancer/ 61776
2. exp oesophagus/ 66401
3. (oesphag* or esophag*).ti,ab. 354558
4. exp cancer/ 6287300
5. (neoplas* or tumor* or tumor* or cancer* or malignan* or 
oncolog* or carcinoma*).ti,ab.
8119204
6. 4 or 5 9459032
7. 2 or 3 376529
8. 6 and 7 166796
9. 1 or 8 183006
10. exp MRI/ 853731
11. (diffusion weighted imaging or nuclear magnetic resonance 
imaging or mri or magnetic resonance imaging or diffusion MRI 
or DW MRI or diffusion weighted imaging or ADC or NMR imag* 
or DCE or dynamic contrast enhanced).ti,ab.
1015992
12. 10 or 11 1411359
13. 9 and 12 3273
14. exp treatment response/ 230455
15. (predict* or pronos* or respons* or diagnos*).ti,ab. 16035453
16. 14 or 15 16119676
17. 13 and 16 1991
18. limit 17 to (dutch or english) 1764
19. limit 18 to yr="2000 -Current" 1659
20. remove duplicates from 19 1337
Suppl. Figure 1. Quality of the included studies evaluated according to the Quality Assessment 
of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria25
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Suppl. Figure 2. Response prediction before treatment: absolute ADC values for good responders 
versus poor responders.
Suppl. Figure 3. Response prediction during treatment: absolute ADC values
Abbreviations of suppl. Fig 2 & 3: RECIST = Response Evaluation Criteria In Solid Tumours23; 
ADC = apparent diffusion coefficient; CR = complete response according to RECIST; PR = partial 
response according to RECIST; Becker = histology according to the Becker score68; TRG = tumour 
regression grade according to Mandard5; IQR = interquartile range; SD = standard deviation. The 
names represent first authors of included studies, followed by the definition of a good responder 
and the proportion of good responders in the particular study.
* This study used clinical complete response on endoscopy as the reference standard.
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Suppl. Figure 4. Response assessment after treatment: absolute ADC values
Abbreviations: RECIST = Response Evaluation Criteria In Solid Tumors23; ADC = apparent diffusion 
coefficient; CR = complete response according to RECIST; PR = partial response according to RECIST; 
TRG = tumor regression grade according to Mandard5; IQR = interquartile range; SD = standard 
deviation.
The names represent first authors of included studies, followed by the definition of a good responder 
and the proportion of good responders in the particular study.
* This study measured ADC on DW-MRI directly after completion of treatment (Zheng-1) and at one 
month after completion of treatment (Zheng-2).
** This study used clinical complete response on endoscopy as the reference standard.
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Suppl. Figure 5. Relative difference in ADC after treatment (%DADCpost-pre) for responders 
versus poor responders 
Abbreviations: RECIST = Response Evaluation Criteria In Solid Tumors23; ADC = apparent diffusion 
coefficient; CR = complete response according to RECIST; PR = partial response according to RECIST; 
TRG = tumor regression grade according to Mandard5; IQR = interquartile range; SD = standard 
deviation.
The names represent first authors of included studies, followed by the definition of a good responder 
and the proportion of good responders in the particular study.
* This study measured ADC on DW-MRI directly after completion of treatment (Zheng-1) and at one 
month after completion of treatment (Zheng-2).
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ABSTRACT
Purpose
In about 30% of patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgical 
resection for locally advanced oesophageal cancer no vital tumour is found in the resection 
specimen. Accurate clinical response assessment is critical if deferral from surgery is considered in 
complete responders. Our study aimed to compare the performance of MRI and of FDG-PET/CT 
for the detection of residual disease after nCRT.
Methods
Patients with oesophageal cancer eligible for nCRT and oesophagectomy were prospectively 
included. All patients underwent FDG-PET/CT and MRI before and between 6 and 8 weeks after 
nCRT. Two radiologists scored the MRI scans, and two nuclear medicine physicians scored the FDG-
PET/CT scans using a 5-point score for residual disease. Histopathology after oesophagectomy 
represented the reference standard. Sensitivity, specificity, and area under the receiver operating 
characteristic curve (AUC) were calculated for detection of residual tumour (ypT+), residual nodal 
disease (ypN+), and any residual disease (ypT+Nx/ypT0N+).
Results
Seven out of 33 (21%) patients had a pathological complete response. The AUCs for individual 
readers to detect ypT+ were 0.71/0.70 on diffusion-weighted (DW)-MRI and 0.54/0.57 on 
FDG-PET/CT, and to detect ypN+ were 0.89/0.81 on DW-MRI and 0.75/0.71 on FDG-PET/CT. 
The AUCs/sensitivities/specificities for the individual readers to detect any residual disease were 
0.74/92%/57% and 0.70/96%/43% on MRI; these were 0.49/69%/29% and 0.60/69%/43% 
on FDG-PET/CT, respectively.
Conclusion 
MRI reached higher diagnostic accuracies than FDG-PET/CT for the detection of residual tumour in 
oesophageal cancer patients at 6 to 8 weeks after nCRT.
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INTRODUCTION
Oesophageal cancer is the ninth most common cancer globally1. Neoadjuvant chemo(radio)
therapy is increasingly used, as it improves survival after surgery for locally advanced oesophageal 
cancer2. In a large Dutch multicentre trial, a pathological complete response (pCR) was found in 
29% of patients after neoadjuvant chemoradiotherapy (nCRT)3. For clinical complete responders 
(cCR), the option of organ preservation after nCRT is currently being explored4,5. Accurate clinical 
response assessment is critical to select the right patients. So far, it is unclear what the optimal 
diagnostic modality or combination of modalities is.
18F-FDG is an analogue of glucose and is taken up into metabolically active cells by endothelial 
glucose transport. This causes FDG uptake on 18F-fluorodeoxyglucose positron emission 
tomography with computed tomography (FDG-PET/CT). This technique helps to detect interval 
distant metastases after nCRT6,7. However, FDG-PET/CT is less accurate in detecting residual 
disease after chemoradiotherapy at the primary tumour site due to its inability to differentiate 
residual tumour and inflammation due to radiotherapy. Two recent meta-analyses reported pooled 
sensitivities of 73% and 74% and specificities of 62% and 52% for the detection of residual tumour 
after neoadjuvant treatment8,9.
Diffusion-weighted magnetic resonance imaging (DW-MRI) is superior in differentiating residual 
tumour from inflammation. Signal depends on the water diffusivity in tissues, which is restricted 
in tumours with a high cellular density10,11. In organ preservation treatment approaches for rectal 
cancer, DW-MRI has proven its additional value to endoscopy and clinical examination in the 
clinical response assessment after nCRT and has become part of the restaging work-up of patients 
considered for organ preservation. DW-MRI is especially accurate in detecting residual disease12,13. 
A preliminary study on DW-MRI for the assessment of response to nCRT in oesophageal cancer 
showed promising results with sensitivities of 90–97% for the detection of residual disease14. 
However, in contrast to rectal cancer diagnostic work-up, standard work-up in oesophageal 
cancer does not yet include MRI. While the inability to differentiate between residual tumour and 
radiation oesophagitis is a major drawback of FDG-PET/CT, DW-MRI could have added value in 
the response assessment of oesophageal cancer patients after chemoradiotherapy.
As yet, it is unknown how DW-MRI relates to FDG-PET/CT, as no prospective comparative 
studies have been performed. In the present study, the performance of DW-MRI was compared 
prospectively with that of FDG-PET/CT in detecting residual disease in patients with oesophageal 
cancer after nCRT.
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METHODS
Patients
The study population consisted of patients with biopsy-proven locally advanced, non-metastatic 
oesophageal cancer who were considered eligible for nCRT followed by oesophagectomy. Patients 
with general contraindications for MRI, for example, severe claustrophobia or a known metallic 
foreign body in the eye, were not eligible for inclusion. The study was approved by the local 
medical ethics committee (NCT 02139488), and written informed consent was obtained from all 
patients.
Treatment
All study patients underwent nCRT (total of 41.4 Gy in 23 fractions with weekly administration of 
carboplatin and paclitaxel) followed by oesophagectomy. Oesophagectomy was performed via 
the transhiatal or transthoracic approach depending on the location of the tumour and suspected 
or biopsy-proven nodal disease.
Imaging
According to local standard work-up, patients underwent FDG-PET/CT to rule out distant metastases 
before and after nCRT. For the purpose of the study, all patients underwent DW-MRI scans before 
and 6–8 weeks after nCRT. The post-nCRT DW-MRI and FDG-PET/CT scans were planned with a 
maximum time interval of 3 weeks between imaging and surgery.
FDG-PET/CT acquisition
The FDG-PET/CT scan after nCRT was performed using the same system and settings in all patients. 
These scans were acquired using a dedicated FDG-PET/CT system (Gemini TF/Big Bore, Philips 
Medical Systems, Cleveland, Ohio, USA). Patients fasted for at least 6 h before the tracer injection 
(4 h in patients with diabetes mellitus). A PET scan was acquired at 2 min per bed position and 
was combined with a low-dose CT scan (dose modulated, 40 mAs, 2-mm slice thickness) for 
attenuation correction and anatomical correlation. The scan was performed from skull base to 
thighs and started 60 ± 10 min after the administration of 18F-FDG (190– 260 MBq). Images were 
reconstructed using iterative 3D reconstruction. In most patients (61%), the baseline FDG-PET/CT 
scan was performed in The Netherlands Cancer Institute, whereas some patients underwent the 
pre-treatment FDG-PET/CT scan in a referring hospital following standard protocols for clinical 
staging according to the EANM procedure guidelines for tumour imaging15.
MRI acquisition
MR imaging (at baseline and 6–8 weeks after nCRT) was performed on a 1.5-Tesla MRI scanner 
(Philips Achieva, Best, The Netherlands), using Torso-XL (16 channel) receiver coils. The MRI 
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consisted of T2-weighted multi-slice turbo spin-echo sequences in axial (slice thickness 4 mm) 
and sagittal (slice thickness 3 mm) planes, and, in order to reduce motion artefacts further, a 
respiratory navigator was positioned on the diaphragm16. A diffusion-weighted echo-planar 
imaging sequence was acquired in the axial plane (b values b = 0, b = 200, and b = 800 s/mm2). 
The axial T2W and DW sequences were angled similarly. Detailed MRI sequence parameters are 
provided in Supplementary File 1.
Image evaluation after nCRT
Two nuclear medicine physicians (hereafter NUC1 and NUC2) retrospectively assessed the FDG-
PET/CT scans, and two radiologists (hereafter RAD1 and RAD2) independently reviewed the DW-
MRI scans. Observers were blinded for clinical information, pathological outcomes after surgery, 
and each other’s scorings. The two radiologists had only access to the MRI scans (and were blinded 
to the FDG-PET/CT scans) and vice versa. The likelihood of residual disease in the oesophagus 
(ypT+) and that of residual nodal disease (ypN+) was scored using a 5-point confidence level 
score (CLS, 1 = definitely complete response, 2 = probably complete response, 3 = inconclusive, 4 
= probably residual tumour, 5 = definitely residual tumour). This confidence level score was used 
in multiple studies on clinical response evaluation14,17,18. Scoring was done on visual inspection 
without measurements. Pre-nCRT images were available at the readers’ disposal for verification of 
the tumour location and comparison of amount of uptake or signal intensity. The two scores (for 
ypT+ and for ypN+) were combined into a final residual disease score based on the highest of 
both scores. For example, if a reader scored CLS 4 on ypT+ and CLS 2 on ypN+, the final residual 
disease score was scored as CLS 4.
Reference standard
Histopathologic examination of the resection specimen represented the reference standard and 
was performed by a dedicated gastrointestinal pathologist. The resection specimen was evaluated 
in accordance with the 7th edition of the International Union Against Cancer protocol for ypTNM 
classification19. The tumour bed was completely embedded for histopathological analysis. Tumour 
regression grade (TRG) of the resected primary tumour was assessed according to Mandard, with 
TRG 1 indicating complete response (ypT0) and TRGs 2–5 indicating residual tumour (ypT+)20. ypN 
stage was dichotomized as ypN0 versus ypN+. Overall, a combined pathologic complete response 
of both the tumour in the oesophagus and lymph nodes was defined as ypT0N0, while patients with 
ypT+Nx or ypT0N+ were regarded as incomplete responders.
Statistical methods
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, 
version 22, Chicago, IL) and STATA (version 11, StataCorp LP, College Station, TX). The diagnostic 
performance for the detection of residual tumour was calculated by means of the receiver operator 
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characteristic (ROC) curve analysis with calculation of the areas under the curve (AUCs). These 
AUCs were compared between the readers by means of the DeLong test21. Diagnostic performance 
measures (i.e. sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) with 95% confidence intervals) were computed separately for the detection of ypT+, ypN+, 
and ypT+ Nx/ypT0N+. The agreement of different reader combinations (RAD1 and NUC1, RAD1 
and NUC2, RAD2 and NUC1, RAD2 and NUC2) and the diagnostic performance to detect 
residual tumour after nCRT were calculated for each of the four reader pairs. Before these analyses 
were performed, dichotomisation between CLS 2 and CLS 3 was decided as the cut-off between 
complete response (CLS 1/2) and incomplete response (CLS 3/4/5). Interobserver agreement 
between the radiologists and interobserver agreement between the nuclear medicine physicians 
were calculated using Cohen’s kappa (0–0.2 poor, 0.21–0.4 fair, 0.41–0.6 moderate, 0.61–0.8 
good, and 0.81–1 excellent agreement).
RESULTS
Patient selection
Between March 2014 and June 2017, 49 patients were potentially eligible for inclusion. Among 
them, 16 patients did not meet the inclusion criteria for the following reasons. Two patients switched 
to definitive CRT during the treatment because of their poor clinical condition; in six patients, the 
DW-MRI after nCRT was not performed; in four patients, surgical resection was not performed; 
in three patients, image quality of the DW-MRI after nCRT was insufficient, which impeded the 
response assessment on DW-MRI; and in one patient, the interval between imaging and surgery 
exceeded 3 weeks (Fig. 1). This left a final study population of 33 patients meeting all inclusion 
criteria.
Patient and tumour characteristics
Detailed patient and tumour characteristics are provided in Table 1. The median (interquartile 
range, IQR) age of the patients was 64 years (53–71), and 29 out of 33 patients (88%) had 
adenocarcinomas. Most patients (73%) had clinical T3 (cT3) stage tumours before the start of 
nCRT19. After nCRT and oesophagectomy, the resection specimen showed ypT0N0 in seven out of 
33 patients (21%) and residual tumour in 26 patients (79%), of whom twelve had ypT+N+, fourteen 
had ypT+N0, and no patient had ypT0N+. This added to a total of 26 ypT+ patients and twelve 
ypN+ patients. The median (IQR) time interval between completion of nCRT and surgery was 59 
(54–66) days, and between imaging and surgery was 11 (11–13) days.
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n=14 excluded for analyses
   n=6: no MRI performed after nCRT
   n=4: no surgery performed becuase
       2 distant metastases on FDG-PET/CT after nCRT
       1 tumour deemed irresectable at surgical exploration
       1 comorbidities and wish patient
   n=3: poor quality of DW-MRI after nCRT
   n=1: interval imaging to surgery >3weeks
n=47 completed nCRT
n=2 excluded, switched to definitive CRT
n=49 signed informed consent
n=33 included for analyses
Figure 1. Flow chart
Diagnostic accuracies for the detection of residual tumour in the oesophagus
The AUCs to detect ypT+ were 0.71 and 0.70 on DW-MRI and 0.54 and 0.57 on FDG-PET/
CT. The DW-MRI assessment resulted in sensitivities/specificities of 92%/57% and 96%/43% for 
RAD1 and RAD2, respectively. As for the FDG-PET/CT assessment, sensitivities/specificities were 
69%/43% and 62%/43% for NUC1 and NUC2, respectively (Table 2).
Diagnostic accuracies for the detection of residual nodal disease
The AUCs to detect ypN+ were 0.81 and 0.89 on DW-MRI and 0.71 and 0.75 on FDG-PET/
CT. The DW-MRI assessment resulted in sensitivities/specificities of 58%/86% and 67%/86% for 
RAD1 and RAD2, respectively. As for the FDG-PET/CT assessment, sensitivities/specificities were 
50%/81% and 42%/86% for NUC1 and NUC2, respectively (Table 2).
Diagnostic accuracies for the detection of any residual disease
The AUCs to detect any residual disease were 0.74 and 0.70 on DW-MRI for RAD1 and RAD2, 
respectively. On FDG-PET/CT, these were 0.49 and 0.60 for NUC1 and NUC2, respectively (Table 
2). The AUCs of the two MRI readers were significantly higher than the AUC of NUC1 (Table 3). The 
sensitivities/specificities to detect any residual disease on DW-MRI were 92%/57% and 96%/43% 
for RAD1 and RAD2, respectively. On FDG-PET/CT, the sensitivity to detect any residual disease 
was 69% for both readers and specificities were 29% and 43% for NUC1 and NUC2, respectively. 
An example showing discrepant scorings between DW-MRI and FDG-PET/CT is shown in Fig. 2.
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Table 1. Patient and tumour characteristics
Characteristic n (%)
Gender: male 24 (73%)
Median age (years) a 64 (53-71)
Tumour location
   Middle oesophageal
   Lower oesophageal
   Gastro-oesophageal junction
3 (9%)
15 (45.5%)
15 (45.5%)
Histological tumour type
   Squamous cell carcinoma
   Adenocarcinoma
    Laurén classification for adenocarcinomas:
      Intestinal
      Diffuse
      Mixed
      Unknown
4 (12%)
29 (88%)
23/29 (80%)
2/29 (7%)
3/29 (10%)
1/29 (3%)
Grade of differentiation
   Well differentiated
   Moderately differentiated
   Poorly differentiated
   Unknown
2 (6%)
15 (45.5%)
15 (45.5%)
1 (3%)
Clinical T-stage b
   cT1
   cT2
   cT3
1 (3%)
8 (24%)
24 (73%)
Clinical N-stage b
   cN0
   cN1
   cN2
   cN3
15 (45.5%)
6 (18%)
10 (30.5%)
2 (6%)
Pathology after surgery: Mandard b,c
   TRG 1 and N0: ypT0N0
   TRG 1 and N1: ypT0N+
   TRG 2
   TRG 3
   TRG 4
   TRG 5
7 (21%)
0 (0%)
10 (30.5%)
12 (36.5%)
3 (9%)
1 (3%)
Pathology after surgery: N-stage b
   ypN0
   ypN1
   ypN2
   ypN3
21 (64%)
4 (12%)
5 (15%)
3 (9%)
Time intervals (days) a
   End of nCRT until oesophagectomy
   End of nCRT until DW-MRI post-nCRT
   End of nCRT until FDG-PET/CT post-nCRT
   DW-MRI post-nCRT until surgery
   FDG-PET/CT post-nCRT until surgery
59 (54-66)
48 (42-51)
48 (42-51)
11 (11-13)
11 (11-13)
a Data are presented in medians, and data in parentheses represent the interquartile range
b Staging of the oesophageal tumour and lymph nodes according to the 7th edition of the TNM classification19
c The tumour regression grade of the primary tumour bed was assessed according to Mandard20
n, number of patients; R0, microscopically radical resection; R1, microscopically irradical resection; TRG, tumour regression 
grade; nCRT, neoadjuvant chemoradiotherapy; DW-MRI, diffusion-weighted magnetic resonance imaging; FDG-PET/CT, 
18-F fluorodeoxyglucose positron emission tomography
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Table 2. Diagnostic accuracies for the detection of local residual tumour (versus ypT0), residual 
nodal disease (versus ypN0), and any residual disease (versus ypT0N0)
Detection of ypT+ AUC (95% 
CI)
Accuracy%, n Sensitivity%
(95% CI), n
Specificity%
(95% CI), n
NPV%
(95% CI), n
PPV%
(95% CI), n
RAD1 (MRI) 0.71
(0.47-0.96)
85, 28/33 92 (73-99), 
24/26
57 (20-88), 
4/7
67 (24-94), 
4/6
88 (70-97), 
24/27
RAD2 (MRI) 0.70
(0.46-0.96)
85, 28/33 96 (78-100), 
25/26
43 (12-80), 
3/7
75 (22-99), 
3/4
86 (67-95), 
25/29
NUC1 (PET) 0.54
(0.29-0.79)
64, 21/33 69 (48-84), 
18/26
43 (12-80), 
3/7
27 (7-61), 
3/11
82 (59-94), 
18/22
NUC2 (PET) 0.57
(0.31-0.84)
58, 19/33 62 (41-79), 
16/26
43 (12-80), 
3/7
23 (6-54), 
3/13
80 (56-93), 
16/20
Detection of ypN+
RAD1 (MRI) 0.89
(0.77-1.00)
76, 25/33 58 (29-83), 
7/12
86 (63-96), 
18/21
78 (56-92), 
18/23
70 (35-92), 
7/10
RAD2 (MRI) 0.81
(0.66-0.97)
79, 26/33 67 (35-89), 
8/12
86 (63-96), 
18/21
82 (59-94), 
18/22
73 (39-93), 
8/11
NUC1 (PET) 0.75
(0.56-0.93)
70, 23/33 50 (22-78), 
6/12
81 (57-94), 
17/21
74 (51-89), 
17/23
60 (27-86), 
6/10
NUC2 (PET) 0.71
(0.52-0.91)
70, 23/33 42 (16-71), 
5/12
86 (63-96), 
18/21
72 (50-87), 
18/25
63 (26-90), 
5/8
Detection of ypT+Nx/ypT0N+
RAD1 (MRI) 0.74
(0.50-0.97)
85, 28/33 92 (74-99), 
24/26
57 (20-88), 
4/7
67 (24-94), 
4/6
89 (70-97), 
24/27
RAD2 (MRI) 0.70
(0.46-0.94)
85, 28/33 96 (78-100), 
25/26
43 (12-80), 
3/7
75 (22-99), 
3/4
86 (67-95), 
25/29
NUC1 (PET) 0.49
(0.25-0.73)
61, 20/33 69 (48-85), 
18/26
29 (5-70), 
2/7
20 (4-56), 
2/10
78 (56-92), 
18/23
NUC2 (PET) 0.60
(0.34-0.86)
64, 21/33 69 (48-85), 
18/26
43 (12-80), 
3/7
27 (7-61), 
3/11
82 (59-94), 
18/22
AUC, area under the receiver operating characteristic curve; MRI, magnetic resonance imaging; PET, positron emission 
tomography; NPV, negative predictive value; PPV, positive predictive value; CI, confidence interval; RAD1, radiologist 1; 
RAD2, radiologist 2; NUC1, nuclear medicine physician 1; NUC2, nuclear medicine physician 2; n, number of patients
Table 3. Comparison of the areas under the curves for the detection of any residual disease 
(ypT+Nx/ypT0N+) between the radiologists on DW-MRI and the nuclear medicine physicians on 
FDG-PET/CT
RAD1, AUC 0.74 RAD2, AUC 0.70 NUC1, AUC 0.49 NUC2, AUC 0.60
RAD1, AUC 0.74 x 0.7516 0.0020* 0.1645
RAD2, AUC 0.70 x x 0.0449* 0.3550
NUC1, AUC 0.49 x x x 0.2045
NUC2, AUC 0.60 x x x x
This table shows the comparison of the areas under the curve between the readers, measured by using the DeLong Test21. 
Each value in the table represents the calculated probability (p value). Significant differences are marked with an asterisk 
(*).  DW-MRI, diffusion-weighted magnetic resonance imaging; FDG-PET/CT, positron emission tomography; AUC, area 
under the receiver operating characteristic curve; RAD1, radiologist 1; RAD2, radiologist 2; NUC1, nuclear medicine 
physician 1; NUC2, nuclear medicine physician 2
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Combined MRI and FDG-PET/CT assessment for the detection of any residual disease
The diagnostic performance of 4 different pairs of radiologists and nuclear medicine physicians 
to detect residual disease after nCRT based on the separate, blinded scorings is shown in Table 
4. In 64 to 79% of patients, the radiologist and nuclear medicine physician agreed on either 
the presence of any residual disease (ypT+Nx/ypT0N+) or complete response (ypT0N0). The 
sensitivities ranged from 94 to 100% with specificities ranging from 33 to 50%. If readers on both 
modalities agreed on the presence of residual disease (CLS 3/4/5), residual tumour was found in 
82 to 85% of the surgical resection specimens (PPV, Table 4).
Interobserver agreement
The agreement between the radiologists on DW-MRI was moderate (k = 0.53), and the agreement 
between the nuclear medicine physicians on FDG-PET/CT was fair (k = 0.37).
Table 4. Diagnostic accuracies in cases the radiologist and nuclear medicine physician agreed 
on the presence of any residual disease (both CLS 3/4/5) or complete response (both CLS 1/2)
Detection of 
ypT+Nx/ypT0N+
Agreement Accuracy%, n
Sensitivity%
(95% CI), n
Specificity%
(95% CI), n
NPV%
(95% CI), n
PPV%
(95% CI), n
RAD1 & NUC1 21/33 (64%) 86, 18/21 100 (52-91), 
16/16
40 (7-83), 
2/5
100(20-
100), 2/2
84 (60-96), 
16/19
RAD1 & NUC2 24/33 (73%) 83, 20/24 94 (71-100), 
17/18
50 (14-86), 
3/6
75 (22-99), 
3/4
85 (61-96), 
17/20
RAD2 & NUC1 25/33 (76%) 80, 20/25 95 (72-100), 
18/19
33 (6-76), 
2/6
67 (13-98), 
2/3
82 (59-94), 
18/22
RAD2 & NUC2 26/33 (79%) 81, 21/26 95 (72-100), 
18/19
43 (12-80), 
3/7
75 (22-99), 
3/4
82 (59-94), 
18/22
MRI, magnetic resonance imaging; PET, positron emission tomography; Sens, sensitivity; Spec, specificity; NPV, negative 
predictive value; PPV, positive predictive value; CI, confidence interval; RAD1, radiologist 1; RAD2, radiologist 2; NUC1, 
nuclear medicine physician 1; NUC2, nuclear medicine physician 2; n, number of patients
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Figure 2. Patient example
A 72-year-old male patient with a cT3N2M0 oesophageal adenocarcinoma treated with 
neoadjuvant chemoradiotherapy (nCRT) and oesophagectomy. Histopathology revealed residual 
tumour (tumour regression grade 3, ypT2N2). The T2-weighted axial image before (a) and 7 
weeks after (d) nCRT shows an isointense oesophageal wall. The corresponding b = 800 diffusion-
weighted images before (b) and after (e) nCRT demonstrate a hyperintense signal, highly suspicious 
for residual tumour (assessed as CLS 4 and CLS 5 by the MRI readers). The tumour showed high 
uptake of fluorodeoxyglucose (FDG) before (c) the start of nCRT, whereas there was only minimal 
FDG uptake which was spread throughout the oesophageal wall after completion of nCRT (f) 
assessed as CLS 2 and CLS 3 by the FDG-PET/CT readers.
DISCUSSION
This study is the first prospective study comparing the performance of DW-MRI with that of FDG-
PET/CT in detecting residual disease after nCRT for oesophageal cancer. The results showed that 
DW-MRI outperformed FDG-PET/CT with regard to the local assessment of response to nCRT. The 
sensitivity to detect any locoregional residual tumour on DW-MRI was 92–96% versus 69% for 
both readers on FDG-PET/CT. Interestingly, when the radiologist and nuclear medicine physician 
agreed on the presence of a residual tumour, the sensitivity and specificity were comparable to a 
single assessment by the radiologists on DW-MRI. This suggests that FDG-PET/CT does not add to 
DW-MRI for the response assessment of the primary tumour. The high sensitivities and PPVs suggest 
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that DW-MRI could be of value in detecting residual tumour after nCRT if organ preservation in 
oesophageal cancer patients is being considered. However, the low specificities of DW-MRI imply 
a chance of missing complete responders for whom an organ-preserving treatment would have 
been an option.
Previous studies on DW-MRI for the response assessment after nCRT in oesophageal cancer have 
focussed mainly on the apparent diffusion coefficient (ADC) derived from DW-MRI, which represents 
a quantitative measure of the diffusion of water22-35. Theoretically, tumorous tissue with restricted 
diffusion (and a low ADC value) can be differentiated from fibrosis without diffusion restriction. 
In a systematic review, the relative increase of ADC during treatment was significantly higher in 
good versus poor responders in most (five out of eight) included studies36. However, response 
assessment after treatment using the ADC is not robust, probably due to the various methods used 
to draw the region of interest, the practice variations regarding the scanners and scan protocols, 
post-processing variations, and the choice of cut-off values. Conversely, a subjective response 
assessment may be more robust for the response assessment of the primary tumour after nCRT, as 
was shown in a previously published study in oesophageal cancer patients and in rectal cancer14. 
In the latter, DW-MRI is used in addition to endoscopy in the selection process for the organ-
saving treatment for patients with a clinical complete response to chemoradiotherapy12,13,17,37. 
Interestingly, a previous study on oesophageal cancer showed that DW-MRI also had additional 
value to endoscopy and endoscopic ultrasound (EUS) for the detection of residual tumour after 
nCRT38.
The main drawback of FDG-PET/CT in the local response assessment after nCRT is the low 
specificity, which may be explained by the presence of (radiation-induced) oesophagitis, masking 
a complete tumour response39,40. In our study, the median interval between completion of nCRT 
and FDG-PET/CT acquisition was 48 days, and prolonging this interval might overcome this 
problem. Although it is known that the presence of oesophagitis is correlated to the radiation dose 
and usually becomes apparent after about 2 weeks of radiotherapy, it is yet unclear how long 
oesophagitis persists on FDG-PET/CT after nCRT41-43. Also, the detection of small residual tumour 
lesions appears challenging on FDG-PET/CT44. Theoretically, if residual tumour cells after nCRT in 
the primary tumour bed are clustered together, FDG-PET/CT may be able to detect these clusters, 
whereas a scattered localisation throughout the oesophageal wall may complicate the detection 
due to the low spatial resolution of FDG-PET/CT, resulting in moderate sensitivities.
Another focus in our study was the detection of residual nodal disease on imaging after nCRT. 
The high specificities (81–86%) and NPVs (72–82%) suggest that the absence of suspect lymph 
nodes on imaging after nCRT may yield predictive value for a true (pathological) absence of 
nodal disease (ypN0). The AUCs were remarkably high (0.81 and 0.89) on DW-MRI, even 
though the hypothesis was that the differentiation between malignant and benign lymph nodes 
on DW-MRI would be challenging as both show diffusion restriction. On FDG-PET/CT, the small 
size of remaining mediastinal tumour-positive lymph nodes may have complicated response 
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assessment. Despite these challenges for FDG-PET/CT, the readers reached AUCs of 0.75 and 
0.71 for residual nodal disease detection. These results concur with a recent study in patients with 
oesophageal squamous cell cancer, in which a residual nodal disease on FDG-PET/CT after nCRT 
was significantly associated with the presence of tumour-positive lymph nodes on pathological 
examination45.
Currently, clinical response assessment after nCRT using a combination of endoscopy, EUS, and 
FDG-PET/CT is being explored in prospective trials5,46. The pitfall of endoscopic biopsies is the high 
risk of false-negative findings, due to submucosal residual tumour and sampling error. Furthermore, 
on EUS, the differentiation between benign and malignant wall thickening after chemoradiotherapy 
has been reported to be difficult47. Therefore, an imaging modality with a high sensitivity and NPV 
is needed to improve response assessment by endoscopic evaluation. The current study showed that 
these values were both higher on DW-MRI as compared with FDG-PET/CT. No additional benefit 
for local response assessment was even found by adding FDG-PET/CT to DW-MRI if performed 
6–8 weeks after completion of CRT. However, for the detection of distant metastases, FDG-PET/
CT still seems essential. In the future, wholebody DW-MRI may be used for this purpose, but this 
was beyond the scope of this study48. A multimodal approach using a combination of FDG-PET/
CT, DW-MRI, and endoscopy with EUS will likely be the ideal method to identify clinical complete 
responders to neoadjuvant chemoradiotherapy.
Some limitations of the current study must be mentioned. Although this was the first study comparing 
clinical response assessment on FDG-PET/CT and DW-MRI after nCRT in oesophageal cancer 
patients, the sample size was relatively small. Also, only the locoregional lymph nodes within the 
field of view of the DW-MRI were assessed because of scan time restrictions. Furthermore, the 
assessment of FDG-PET/CT might be influenced by various system settings at acquisition before 
nCRT. However, the post-nCRT FDG-PET/CT scans were performed on the same scanner in all 
patients. Whereas for quantitative imaging analyses the exact acquisition parameter settings could 
be an issue, the variation in pretreatment FDG-PET/CT acquisition can be accepted for subjective 
response assessment studies.
In conclusion, this study showed that DW-MRI reached higher diagnostic accuracies than FDG-
PET/CT for the detection of local residual tumour in oesophageal cancer patients at 6 to 8 weeks 
after nCRT.
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SUPPLEMENTARY FILES
Suppl. Table 1. MRI parameters
T2W-MRI DW-MRI
Imaging plane Axial Sagittal Axial
Slice thickness (mm) 4 3 4
Field of view (mm3, APxRLxFH) 225x225x180 150x60x225 260x520x200
In-plane resolution (mm2) 0.67x0.67 0.70x0.70 3.25x3.25
Repetition time (ms) 1454-1938 1431-1463 7421-7503
Echo time (ms) 100 100 77
Echo train length 39 22 71
b-values (s/mm²) - - 0, 200, 800
NSA 2 2 4, 4, 12
Respiratory triggering 
(navigator)
Yes Yes No
Fat suppression technique - - SPIR
Abbreviations; T2W = T2-weighted; DW = diffusion-weighted; MRI = magnetic resonance imaging; AP = anterior to 
posterior; RL = right to left; FH = feet to head; NSA = number of squared averages; SPIR = Spectral Presaturation with 
Inversion Recovery
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ABSTRACT
Objectives
In order to select oesophageal cancer patients after neoadjuvant chemoradiotherapy (nCRT) for 
organ-preserving treatment instead of surgery, a high diagnostic accuracy is required. The aim 
of this study was to evaluate whether MRI had additional value to gastroscopy with biopsies and 
endosonographic ultrasound (EUS) with fine needle aspiration (FNA) for the detection of residual 
tumour after nCRT.
Methods
Twenty-two patients with oesophageal cancer eligible for nCRT followed by oesophagectomy 
were prospectively included. All patients underwent (T2- and diffusion-weighted) MRI and 
gastroscopy+EUS before and after nCRT. Histopathology after oesophagectomy was the reference 
standard with pathological complete response (pCR) defined as ypT0N0. Diagnostic performance 
regarding the detection of residual tumour was calculated for gastroscopic biopsies and for EUS-
FNA without and with MRI.
Results
Nineteen of the 22 patients (86%) did not achieve pCR after nCRT (7 ypT+N+, 11 ypT+N0, 1 
ypT0N+). Biopsies detected residual tumour in 6 of 18 ypT+ patients. After adding MRI, 16 of 
18 residual tumours were assessed correctly. EUS-FNA detected 3 out of 8 ypN+ patients, while 
MRI did not improve detection. Overall, adding MRI improved sensitivity for detection of residual 
tumour to 89% (17 of 19) from 47% (9 of 19) with endoscopic biopsies and EUS-FNA only.
Conclusion
In this small study, the detection of residual tumour after nCRT in oesophageal cancer patients was 
improved by the addition of MRI to gastroscopy and EUS.
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INTRODUCTION
Oesophageal cancer is the sixth most common cause of cancer death in the world and the ninth 
most common cancer worldwide1. Patients with locally advanced oesophageal carcinoma are 
eligible for treatment with curative intent. Neoadjuvant chemoradiotherapy (nCRT) has been shown 
to improve overall survival compared with surgery alone. Furthermore, in 23% of the patients with 
adenocarcinomas and in 49% of the patients with squamous cell carcinomas, nCRT even results in 
a pathological complete response (pCR) in the resection specimen2. As surgery is associated with 
considerable morbidity, it is questioned if patients with a clinical complete response (cCR) after 
nCRT could benefit from an organ-sparing approach3. However, this approach demands accurate 
differentiation between complete and incomplete responders after nCRT.
An active surveillance approach for clinical complete responders is currently being investigated 
by two European research groups4,5. In these trials, response assessment after nCRT is performed 
with gastroscopy, endoscopic ultrasound (EUS) and 18F-fluorodeoxyglucose positron emission 
tomography computed tomography (FDG-PET/CT). However, previous studies have shown that 
in 28 to 55% of patients assessed as having a cCR with gastroscopic and endosonographic 
assessment, residual tumour is found in the resection specimen after surgery6-9. FDG-PET/CT shows 
potential in predicting response before the start of treatment and seems important for the detection 
of interval distant metastases after nCRT10-12. However, assessment of FDG-PET/CT has not been 
able to accurately distinguish residual tumour from radiation oesophagitis and/or fibrosis after 
nCRT13,14. In rectal cancer, active surveillance by endoscopy and digital rectal examination is 
supplemented by MRI15,16. Due to technological improvement, MRI of the oesophagus is currently 
also feasible17,18. A recent study showed that DW-MRI results in a high sensitivity (90–97%) for 
detecting residual tumour in oesophageal cancer patients after nCRT19.
The aim of this study was to investigate whether MRI has added value to gastroscopy with biopsies 
of the primary tumour area and EUS with fine needle aspirates (FNA) of suspect lymph nodes for 
the detection of residual tumour after nCRT in oesophageal cancer patients.
MATERIALS AND METHODS
Patients
The study was approved by the local medical ethics committee (NCT02139488) and written 
informed consent was obtained from all patients. Patients were prospectively enrolled. Inclusion 
criteria were (1) biopsy-proven locally advanced, non-metastatic oesophageal cancer with or 
without involvement of the gastro-oesophageal junction, (2) planned curative treatment with nCRT 
(41.4 Gray in 23 fractions, with weekly administration of carboplatin (AUC 2) and paclitaxel (50 
mg/m2) for 5 weeks) followed by oesophagectomy. Exclusion criteria were claustrophobia and 
metallic implants.
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Response assessment on MRI
Imaging was acquired on a 1.5-T MRI scanner (Philips Achieva), using Torso-XL (16 channel) 
receiver coils. The MRI protocol consisted of T2-weighted imaging in transverse and sagittal 
planes and diffusion-weighted sequences in the transverse plane (b values 0, 200, 800 s/mm2). A 
respiratory navigator was placed on the diaphragm and scanning was performed at the end of the 
expiratory phase20. Detailed MRI sequences are provided in Supplementary Table 1. All MRI scans 
were independently and prospectively analysed by an expert radiologist with 4 years of specific 
experience interpreting oesophageal MRI (AB). The radiologist reviewed the T2W- and DW-MRI 
with b = 800 s/mm2 before and after nCRT. The MRI after nCRT was scored for the presence 
of residual tumour based on a 5-point confidence level score (CLS): CLS1 = definitely complete 
response, 2 = probably complete response, 3 = inconclusive, 4 = probably residual tumour, 5 = 
definitely residual tumour19,21. This score is illustrated in Supplementary Figure 1.
Expert meeting between radiologist and gastroenterologist
After the MRI scan but before gastroscopy+EUS, the MRI scan was discussed by an expert radiologist 
(A.B.) and expert gastroenterologist (J.vD.). The radiologist showed the images to guide in taking 
targeted biopsies at locations that remained suspect on MRI after nCRT. The radiologist provided 
the gastroenterologist with anatomical landmarks for the most suspect areas for residual tumour 
on MRI, e.g. ventral oesophageal wall 1 cm above the diaphragm, to direct EUS-guided biopsies.
Response assessment on gastroscopy and EUS
A baseline gastroscopy+EUS was performed in all patients before the start of nCRT. Response 
assessment on gastroscopy+EUS was performed 6–10 weeks after completion of nCRT and a 
maximum of 2 weeks after the MRI. All procedures were performed or supervised by an expert 
gastroenterologist.
During gastroscopy, a minimum of eight bite-on-bite biopsies were taken from areas that were 
clinically suspect for residual tumour6. If no suspect lesions were detected, bite-on-bite biopsies 
were acquired at random locations in the primary tumour bed. After gastroscopy, a clinical CLS 
for the presence of residual tumour was assessed (score as aforementioned).
Next, all patients underwent EUS. FNA was performed of suspicious lymph nodes. If the 
gastroenterologist feared adverse events of performing FNA that could postpone or complicate the 
upcoming surgery, FNA was not performed and only a CLS of the lymph nodes was determined. 
In case the radiologist assessed residual tumour in a specific region, the gastroenterologist took 
EUS-guided biopsies of this area. After EUS, the gastroenterologist assessed the clinical CLS for 
the presence of residual tumour. If the primary tumour bed could not be passed, this was assessed 
as CLS4.
After the gastroscopy and EUS, the highest of the confidence level scores was determined as the 
CLS on gastroscopy+EUS. Biopsy specimens and fine needle aspirates were examined for the 
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presence of residual tumour by an expert pathologist.
Adverse events
Serious adverse events (SAE) were defined as death and adverse events that required medication, 
re-interventions and/or (prolongation of) hospitalisation due to study interventions. All adverse 
effects of diagnostic procedures performed for study purposes were reported (i.e. the MRI scans 
and the gastroscopy and EUS re-evaluation).
Surgery
Depending on tumour and lymph node location, oesophageal resection with lymph node dissection 
was performed via a transhiatal or transthoracic approach, followed by gastric tube reconstruction 
and a cervical anastomosis.
Reference standard
Histopathologic examination of the resection specimens was performed by an experienced 
gastrointestinal pathologist, in accordance with the ypTNM classification22. The ‘y’ means that the 
classification was performed after multimodality therapy and the ‘p’ means that it was confirmed 
during evaluation of histopathology. The tumour bed was completely embedded and tumour 
regression grading (TRG) of the resected specimen was performed according to Mandard23. TRG1 
without lymph node metastases (ypT0N0) was regarded as pCR, whereas TRG2-5 or TRG1 with 
lymph node metastases (ypT+N+, ypT+N0 or ypT0N+) represented residual tumour.
Statistical methods
Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS, v22). 
This study was exploratory by nature; therefore, no formal sample size calculation has been 
performed. Diagnostic performance measures with 95% confidence intervals (95% CI) were 
computed and receiver operator characteristic (ROC) curve analysis was performed with calculation 
of the areas under the curve. Before performing the analyses, we chose the cutoff for complete 
response versus residual tumour between CLS3 and CLS4 (CLS 1/2/3 complete response; CLS 
4/5 residual tumour). If the biopsies/FNA resulted in residual tumour, this was assessed a CLS5 
(definitely residual tumour) and if the biopsies/FNA were negative, this was regarded a CLS1 
(definitely complete response).
First, ROC curve analysis was performed for the detection of ypT+ regarding endoscopic biopsies. 
In all patients with negative biopsies, the gastroenterologist scores (CLS-gastroscopy or CLS-EUS) 
or the radiologist score (CLS-MRI) replaced the CLS1 of biopsies only, while patients with positive 
biopsies remained CLS5. So, a total of four ROC curves were calculated for the detection of ypT+ 
(biopsy only; biopsy + CLS-gastroscopy; biopsy + CLS-EUS; biopsy + CLS-MRI). 
Second, ROC curve analysis was performed for the detection of ypN+. The accuracy of FNA only 
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was calculated. In all patients with negative FNA, the CLS-EUS and the CLS-MRI for predicting 
ypN+ replaced the CLS1 of FNA only, while patients with positive FNA remained CLS5. This 
resulted in three ROC curves for the detection of ypN+ (FNA only; FNA + CLS-EUS; FNA + CLS-
MRI).
Last, ROC curve analysis was performed for the detection of ypT+/ypT0N+. The CLS of 
biopsies/FNA was combined to result in CLS5 if either biopsies or FNA or both were positive for 
residual tumour and CLS1 if all were negative. In all patients with negative biopsies/FNA, the 
gastroenterologists’ scores (highest CLS on gastroscopy or EUS) and the CLS-MRI replaced the 
CLS1 of biopsies/FNA. Thus, three ROC curves were calculated for the detection of ypT+/ypT0N+ 
(biopsies/FNA; biopsies/FNA + CLS-gastroscopy + EUS; biopsies/FNA + CLS-MRI).
RESULTS
Patient and treatment characteristics
Thirty-one patients signed an informed consent to undergo MRI before and after nCRT and 
gastroscopy+EUS evaluation after nCRT. Nine patients were excluded for the reasons mentioned in 
the flowchart (Fig. 1). Eventually, 22 patients were included for the analysis.
Patient and tumour characteristics are shown in Table 1. Twenty patients (91%) were diagnosed with 
adenocarcinoma and 2 patients (9%) with squamous cell carcinoma. Transhiatal oesophagectomy 
was performed in 14 patients (64%) and transthoracic oesophagectomy in 8 patients (36%). In all 
22 patients, the oesophagectomy resulted in a radical resection of the primary tumour bed (R0 
in 100%). The median time interval (interquartile range (IQR)) between the last radiation fraction 
and surgery was 65 (55–72) days. The median interval (IQR) was 11 (11–18) days between MRI 
and surgery and 5 (5–12) days between gastroscopy+EUS and surgery. On histopathological 
assessment, a TRG1 was found in four out of the 22 patients. In three out of these four, no tumour 
cells were determined in resected lymph nodes (ypT0N0), while one patient had ypT0N1. The 
remaining 18 patients had ypT+ with TRG2 in 5/22 (23%), TRG3 in 9/22 (41%), TRG4 in 3/22 
(14%) and TRG5 in 1/22 patients (4%).
Adverse events
No MRI-related SAEs occurred. One gastroscopy+EUS-related SAE was encountered. This patient 
presented with fever after the endoscopic procedure and was diagnosed with a probable aspiration 
pneumonia. The patient was admitted to the hospital for one night and treated with oral antibiotics 
for 1 week. There was no need to postpone surgery.
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Diagnostic accuracies
The accuracies for the assessment of residual tumour (separately calculated for the detection of 
ypT+/ypT0N+, ypT+ and ypN+) are shown in Table 2. Of all the 22 patients, 19 patients had 
ypT+/ypN+, 18 patients had ypT+ and 8 patients had ypN+ in the resection specimen.
Assessment of ypT+/ypT0N+
Biopsies/FNA correctly detected residual tumour in 9 out of 19 patients (sensitivity 47% for detecting 
ypT+/ypT0N+; Table 2). ypT+ was detected by biopsies in 6 of 18 patients, and EUS-FNA detected 
ypN+ in 3 out of 8 patients with lymph node metastases. One of these patients was confirmed 
ypT0N+ after oesophagectomy, whereas the other two patients had ypT+N+ in the resection 
specimen. The AUC and sensitivity were 0.74 and 47% for biopsies/FNA only. After adding the 
MRI, 17 of the 19 patients with residual tumour in the resection specimens were detected, resulting 
in an AUC and sensitivity of 0.87 and 89%. Figure 2 illustrates a patient with negative outcomes 
of endoscopic biopsies, CLS2 on visual assessment of gastroscopy+EUS and CLS4 on MRI. In this 
patient, residual tumour (ypT1bN0, TRG 3) was determined on histopathological examination of 
the resection specimen with a tumour mass located in the submucosal layer, shown in Fig. 3.
Assessment of ypT+
For the assessment of ypT+ only, the AUC depending on biopsies was 0.67 and 6/18 patients with 
residual tumour were correctly detected (sensitivity 33%). Biopsies + CLS-gastroscopy resulted in an 
AUC of 0.60 and biopsies + CLS-EUS resulted in an AUC of 0.69. In seven patients, an additional 
EUS-guided biopsy was performed in the area that was suspect on MRI. One of these biopsies 
showed residual tumour. Also, in seven patients, an EUS-guided biopsy was taken from the thickest 
part of the oesophageal wall of which one detected residual tumour. The residual tumour detected 
by EUS-guided biopsies in these two patients did not affect the accuracies because residual tumour 
was already confirmed in the regular bite-on-bite biopsies. Lastly, combining the biopsies with the 
CLS-MRI led to an AUC of 0.79 with a sensitivity of 89% (16/18 patients with ypT+ were correctly 
detected).
Assessment of ypN+
In 9 out of the 22 patients, FNA of suspect lymph nodes was performed. The AUC for FNA to 
predict ypN+ was 0.69 with a sensitivity of 38% (3 out of 8 patients with ypN+ were detected). This 
AUC increased to 0.80 and the sensitivity increased to 88% after adding the gastroenterologists’ 
CLS on EUS (7 of 8 patients with ypN+ were correctly assessed). Adding MRI to FNA for predicting 
ypN+ resulted in an AUC of 0.73 and the sensitivity remained 38%.
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2 excluded, no MRI after nCRT
   1 technical problem
   1 claustropobia
27 eligible for response assessment on MRI
25 eligible for response assessment on 
endoscopy+EUS
24 underwent response assessment on MRI 
and endoscopy+EUS
22 inluded for analysis
4 excluded, metastases on FDG-PET/CT 
after nCRT
1 excluded, no biopsy/FNA performed 
because of bleeding risk
31 signed informed consent
2 excluded, no surgery
   1 patient in poor condition
   1 comorbidities and wish patient
Figure 1. Flowchart of the study
FDG-PET/CT = 18F fluorodeoxyglucose positron emission tomography; nCRT = neoadjuvant 
chemoradiotherapy; MRI = magnetic resonance imaging; EUS = endosonographic ultrasound; 
FNA = fine needle aspiration
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Table 1. Patient and tumour characteristics
Characteristic n (%)
Gender: male 18 (81%)
Median age (years) a 63 (59-70)
Tumour location
   Upper oesophageal
   Middle oesophageal
   Lower oesophageal
   Gastro-oesophageal junction
1 (4.5%)
3 (13.6%)
9 (40.9%)
9 (50.9%)
Histological tumour type
   Adenocarcinoma
    Laurén classification for adenocarcinomas:
      Intestinal
      Diffuse
      Mixed
  Squamous cell carcinoma
20 (91%)
14/20 (70%)
4/20 (20%)
2/20 (10%)
2 (9%)
Grade of differentiation
   Well differentiated
   Moderately differentiated
   Poorly differentiated
   Undifferentiated
0 (0%)
10 (45%)
7 (32%)
5 (23%)
Clinical T-stage b
   cT1
   cT2
   cT3
0
7
15
0
Clinical N-stage b
   cN0
   cN1
   cN2
   cN3
7
7
7
1
Pathology after surgery c
   TRG 1 and N0: ypT0N0
   TRG 1 and N1: ypT0N+
   TRG 2, or ypT0N+
   TRG 3
   TRG 4
   TRG 5
3 (14%)
1 (4.5%)
5 (23%)
9 (40%)
3 (14%)
1 (4.5%)
Time intervals (days) a
   End of nCRT until esophagectomy
   End of nCRT until MRI post-nCRT
   End of nCRT until gastroscopy+EUS
   MRI post-nCRT until gastroscopy+EUS
   MRI post-nCRT until surgery
   Gastroscopy+EUS until surgery
65 (55-72)
49 (45-57)
55 (50-65)
6 (5-7)
11 (11-18)
5 (5-12)
a Data are presented in medians and data in parentheses represent the interquartile range
b Clinical staging of the oesophageal tumor and lymph nodes according to the 7th edition of the TNM classification22
c The tumor regression grade of the primary tumor bed was assessed according to Mandard23
n, number patients; TRG, tumor regression grade; nCRT, neoadjuvant chemoradiotherapy; MRI, magnetic resonance imaging
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Table 2. Diagnostic accuracies for the detection of ypT+/ypT0N+ (versus ypT0N0), ypT+ (versus 
ypT0) and ypN+ (versus ypN0)
Detection of 
ypT+/ypT0N+
AUC 
(95% CI)
Accuracy%, 
n
Sensitivity% 
(95% CI), n
Specificity% 
(95% CI), n
NPV%
(95% CI), n
PPV%
(95% CI), n
Biopsies/FNA 
only
0.74
(0.50-0.97)
55, 12/22 47 (25-71), 
9/19
100 (31-
100), 3/3
23 (6-54), 
3/13
100 (63-
100), 9/9
Biopsies/
FNA + CLS 
0.71
(0.46-0.96)
68, 15/22 74 (49-90), 
14/19
33 (2-87), 
1/3
17 (1-64), 
1/6
88 (60-98), 
14/16
Biopsies/FNA + 
CLS MRI
0.87
(0.68-1.00)
86, 19/22 89 (65-98), 
17/19
67 (13-98), 
2/3
50 (9-91), 
2/4
94 (71-100), 
17/18
Detection of ypT+
Biopsies only 0.67
(0.41-0.92)
45, 10/22 33 (14-59), 
6/18
100 (40-
100), 4/4
25 (8-53), 
4/16
100 (52-
100), 6/6
Biopsies + CLS 
gastroscopy
0.60
(0.34-0.87)
59, 13/22 67 (41-86), 
12/18
25 (1-78), 
1/4
14 (1-58), 
1/7
80 (51-95), 
12/15
Biopsies + CLS 
EUS
0.69
(0.45-0.93)
50, 11/22 56 (31-78), 
10/18
25 (1-78), 
1/4
11 (1-49), 
1/9
77 (46-94), 
10/13
Biopsies + CLS 
MRI
0.79
(0.57-100)
82, 18/22 89 (64-98), 
16/18
50 (9-91), 
2/4
50 (9-91), 
2/4
89 (64-98), 
16/18
Detection of ypN+
FNA only a 0.69 
(0.43.0.94)
77, 17/22 38 (10-74), 
3/8
100 (73-
100), 14/14
74 (49-90), 
14/19
100 (31-
100), 3/3
FNA + CLS EUS 0.80
(0.60-100)
68, 15/22 88 (47-99), 
7/8
57 (30-81), 
8/14
89 (51-99), 
8/9
54 (26-80), 
7/13
FNA + CLS MRI 0.73
(0.51-0.96)
73, 16/22 38 (10-74), 
3/8
93 (64-100), 
13/14
72 (46-89), 
13/18
75 (22-99), 
3/4
ypT0N+/ypT+/ypN+, pathology of the specimen after esophagectomy according to the 7th edition of the TNM classification19; 
MRI, magnetic resonance imaging; CLS, confidence level score; NPV, negative predictive value; PPV, positive predictive value; 
95%CI, 95%confidence interval; EUS, endoscopic ultrasonography; FNA, fine needle aspiration; n, number of patients
a If FNA was not performed, this was scored as a negative FNA outcome
89
2
3
4
6
7
A
1
ADDED VALUE OF MRI TO ENDOSCOPIC AND ENDOSONOGRAPHIC RESPONSE ASSESSMENT
5
5
Figure 2. Patient with false negative endoscopic biopsies; false negative visual assessment on 
endoscopy; true positive MRI assessment and residual tumour confirmed at histopathological 
examination of the resection specimen after oesophagectomy.
A 52-year-old male patient with a cT3N0 distal adenocarcinoma of the oesophagus, with residual 
tumour after neoadjuvant chemoradiotherapy and oesophagectomy (shown in Fig. 3). The T2-
weighted transverse (a) image before chemoradiotherapy showed a thickened oesophageal wall, 
accompanied by hyperintense signal on diffusion-weighted imaging (b) and an oesophageal 
tumour on endoscopy (c). The T2-weighted transverse (d) image after chemoradiotherapy showed 
a shrinkage of the wall with considerable hypointense signal, reflecting fibrosis. The diffusion-
weighted MRI after neoadjuvant treatment (e) still showed hyperintense signal in the primary 
tumour area which was suspect for residual tumour and assigned as a confidence level score 
4. On endoscopy after neoadjuvant therapy (f), the primary tumour area was not suspect for 
residual tumour (confidence level score 2) and bite-on-bite biopsies of the primary tumour bed 
were negative.
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Figure 3. Histopathological examination of the resection specimen of the patient outlined in Fig. 
2 showed a tumour regression grade 3, ypT1bN0. Histopathological examination of the resection 
specimen of the patient outlined in Fig. 2.
a An overview of the resected specimen with the gastric folds on the left side and the gastrooesop-
hageal junction on the right side. The residual tumour cells are located in the black square.
b Represents the black square with a black dashed line indicating the separation between the 
mucosal and submucosal layer. The residual tumour cells are designated by the red line in the 
submucosal layer.
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DISCUSSION
This study is the first to evaluate whether MRI has added value to gastroscopy and EUS in the 
assessment of residual tumour after nCRT for oesophageal cancer. In this small sample, the addition 
of MRI assessment to pathology results of biopsies/FNA acquired by gastroscopy and EUS resulted 
in a notable increase in accuracy and sensitivity for the detection of residual tumour. This implies 
that the considerable chance of missing residual tumour after nCRT with only gastroscopy and 
EUS decreases after adding MRI. However, even in the current small study, the risk of false positive 
MRI was demonstrated with one out of three complete responders incorrectly assessed as residual 
tumour on MRI.
Currently two research groups are evaluating an active surveillance approach for clinical complete 
responders4,5. A precursor study assessed the detection of residual tumour by gastroscopy which 
was followed by a second gastroscopy with EUS in patients with negative biopsies. This resulted 
in a sensitivity of 77% and specificity of 72% for detecting residual tumour after nCRT by using 
bite-on-bite biopsies and FNA6. The sensitivity for detecting residual tumour of gastroscopy and 
EUS could be improved to 89% in the current study by adding a noninvasive MRI assessment, 
which therefore seems to yield better results than the addition of a second gastroscopy with EUS 
as was done in the aforementioned precursor study6. If surgery is to be safely omitted, detection 
of residual tumour needs to be optimal7,9. Therefore, the addition of MRI to gastroscopy and EUS 
seems of value in the implementation of an active surveillance approach. Furthermore, in rectal 
cancer, the combination of rectoscopy and MRI has shown to be effective in assessing the response 
to chemoradiotherapy and is now seen as a valuable tool in an active surveillance strategy15,16.
Another modality that has been examined to improve the sensitivity of endoscopic assessment for 
detecting residual tumour is FDG-PET/CT. Two studies found sensitivities/specificities of 24%/83% 
(n = 138, 24) and of 30%/97% (n = 284, 25) based on endoscopic assessment combined with 
FDG-PET/CT. Although these studies only incorporate endoscopic biopsies (without EUS-FNA), 
the poor sensitivities after adding FDG-PET/CT reflect the inability of FDG-PET/CT to assess 
response after nCRT for oesophageal cancer. Potential reasons for this inability are the inability 
to differentiate between radiation-induced oesophagitis and residual tumour on FDG-PET/CT and 
a detection threshold that is too high to pick up small residual tumours26. Based on our (small) 
cohort of patients, MRI seems to outperform FDG-PET/CT in assessing the response of the primary 
oesophageal tumour after nCRT, especially in terms of sensitivity for residual tumour detection.
For the detection of ypT+, our study showed that gastroscopy with biopsies resulted in a sensitivity 
and specificity of 33% and 100%. These results are in line with a systematic review which reported 
pooled estimates for sensitivity and specificity of endoscopic biopsies after nCRT for assessment of 
ypT+ of 35% and 91%27. The addition of the gastroenterologists’ CLS on gastroscopy to biopsy 
alone did not result in an improvement of predicting ypT+. This reflects the difficulty of visual 
differentiation of residual tumour and inflammatory/reactive tissue on gastroscopy. Prolonging the 
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interval between the end of nCRT and gastroscopy may reduce the presence of radiation-induced 
oesophagitis and ulcers and thereby improve the ability to differentiate between residual tumour 
and complete response on gastroscopy. Yet, in patients with residual tumour after nCRT and surgery, 
the mucosa is not involved in 28% of the cases28. Therefore, visual assessment on gastroscopy may 
not be an ideal evaluation strategy. On EUS, the oesophageal wall can be visualised and a recent 
study showed that residual wall thickness was associated with TRG3-4 residual disease29. However, 
the visual differentiation between tumour, fibrosis and inflammation after nCRT remains difficult30. 
This is in line with our finding that addition of the CLS on EUS did not result in an AUC increase 
for detecting ypT+. Conversely, MRI both visualises the complete wall and allows the differentiation 
between tumour and fibrosis with diffusion weighting. The expert meeting between the radiologist 
and the gastroenterologist resulted in the performance of EUS-guided biopsies which did not affect 
the accuracy to detect residual tumour in our cohort. However, the addition of the assessment 
on MRI to the endoscopic biopsies resulted in a notable AUC increase which encourages the 
combination of biopsies/FNA and MRI for response assessment in oesophageal cancer.
For the detection of ypN+, the EUS-FNA resulted in an AUC of 0.69 with a sensitivity of only 38%. 
An explanation for the moderate accuracy of EUS-FNA is that FNA was not performed in 5 out 
of 14 patients with suspect lymph nodes because the gastroenterologist feared adverse events of 
performing FNA that could postpone or complicate the upcoming surgery. This is a limitation of 
this study concerning the EUS evaluation. These results, however, are in line with a previous study 
which reported a low sensitivity of 26% for EUS-FNA after nCRT31. Risk for (mediastinal) bleeding 
during the FNA procedure withheld the gastroenterologist from aggressive FNA of all suspect 
lymph nodes. More aggressive application of FNA is desirable in active surveillance strategies 
because of major clinical consequences if lymph node metastases are missed. After adding the 
gastroenterologists’ CLS on EUS, the AUC improved from 0.69 to 0.80 and also the sensitivity 
improved from 38 to 88%. This encourages FNA of all suspect lymph nodes when considering an 
active surveillance approach for patients with a clinical complete response. The sensitivity of the 
current study to predict residual tumour positive nodes was higher than that of a previous study 
which assessed clinical N staging by the gastroenterologist based on EUS in 73 patients (sensitivity 
67%, 30). The addition of MRI to EUS-FNA in our study did not improve the AUC for detection of 
ypN+ disease (AUC 0.73) and the sensitivity was still low (38%). The poor sensitivity for detection of 
ypN+ on MRI may be partially explained by the fact that on MRI not all locoregional lymph nodes 
could be included in the field of view due to scan time restrictions. The assessment of locoregional 
lymph node response on imaging in oesophageal cancer remains a challenge and is subject of 
ongoing research32-34.
Some limitations must be considered. First, although this is the first study combining gastroscopy, 
EUS and MRI to detect residual tumour after nCRT, the sample size is small. Indeed, the number of 
patients with ypT0N0/TRG1 is very limited (n = 3) resulting in a specificity with large confidence 
intervals. Second, it should be noted that the assessment by the gastroenterologist may be biased by 
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the radiologists’ opinion of response on MRI that was shared during the expert meeting. However, 
as the radiologists’ accuracy was high, in that case, a high accuracy of detecting residual tumour 
by the gastroenterologists’ visual assessment would be expected, which was not found in this study. 
Lastly, as discussed above, FNA was not performed in all patients with suspect lymph nodes.
In conclusion, in this study, the addition of MRI to the gastroscopic and endosonographic assessment 
after nCRT in oesophageal cancer patients improved the detection of residual tumour. Larger studies 
on this combination are warranted and a multimodal assessment strategy including gastroscopy, 
EUS and MRI may allow safe implementation of active surveillance in oesophageal cancer patients 
after chemoradiotherapy.
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SUPPLEMENTARY FILES
Suppl. Table 1. MRI sequence parameters
T2W-MRI DW-MRI
Imaging plane Transverse Sagittal Transverse
Slice thickness (mm) 4 3 4
Field of view (mm3, APxRLxFH) 225x225x180 150x60x225 260x520x200
In-plane resolution (mm2) 0.67x0.67 0.70x0.70 3.25x3.25
Repetition time (ms) 1938 1463 7421
Echo time (ms) 100 100 77
Echo train length 39 22 71
b-values (s/mm²) - - 0, 200, 800
NSA 2 2 4, 4, 12
Respiratory triggering 
(navigator)
Yes Yes No
Fat suppression technique - - SPIR
Abbreviations; T2W = T2-weighted; DW = diffusion-weighted; MRI = magnetic resonance imaging; AP = anterior to 
posterior; RL = right to left; FH = feet to head; NSA = number of squared averages; SPIR = Spectral Presaturation with 
Inversion Recovery
Suppl. Figure 1. Confidence level score
This Figure illustrates the confidence of the readers from low to high (y-axis) and the suspicion of 
residual disease from low to high (x-axis).
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ABSTRACT
Purpose
Current delineation of the gross tumor volume (GTV) in esophageal cancer relies on computed 
tomography (CT) and combination with 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET). There is increasing interest in integrating magnetic resonance imaging (MRI) in 
radiation treatment, which can potentially obviate CT- or FDG-PET/CT based delineation. The aim 
of this study is to evaluate the feasibility of target delineation on T2-weighted (T2W) MRI and T2W 
including diffusion-weighted MRI (T2W+DW-MRI) compared with current-practice FDG-PET/CT.
Methods
Ten observers delineated primary esophageal tumor GTVs of 6 patients on FDG-PET/CT, T2W-
MRI, and T2W+DW-MRI. GTVs, generalized conformity indices, in-slice delineation variation (root 
mean square), and standard deviations in the position of the most cranial and caudal delineated 
slice were calculated.
Results
Delineations on MRI showed smaller GTVs compared with FDG-PET/CT-based delineations. 
The main variation was seen at the cranial and caudal border. No differences were observed 
in conformity indices (FDG-PET/CT, 0.68; T2W-MRI, 0.66; T2W+ DW-MRI, 0.68) and in-slice 
variation (root mean square, 0.13 cm on FDG-PET/CT; 0.10 cm on T2W-MRI; 0.14 cm on 
T2W+DW-MRI). In the 2 tumors involving the gastroesophageal junction, addition of DW-MRI to 
T2W-MRI significantly decreased caudal border variation.
Conclusions
MRI-based target delineation of the esophageal tumor is feasible with interobserver variability 
comparable to that with FDG-PET/CT, despite limited experience with delineation on MRI. Most 
variation was seen at cranial-caudal borders, and addition of DW-MRI to T2W-MRI may reduce 
caudal delineation variation of gastroesophageal junction tumors.
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INTRODUCTION
Esophageal cancer is diagnosed in >450,000 patients per year worldwide and is the sixth most 
common cause of cancer-related death1. Standard therapy with curative intent for patients with 
locally advanced esophageal cancer consists of neoadjuvant chemoradiation therapy followed 
by surgery, improving 5-year survival compared with surgery alone2,3. For patients who are 
unfit for major surgery, definitive chemoradiation therapy is preferred4. Thus, radiation treatment 
plays a central role in the treatment of esophageal cancer5. Accurate gross tumor volume (GTV) 
delineation of the primary tumor is essential when boost strategies are applied. Increasing evidence 
suggests that boosting gross primary disease may improve local tumor control6. Implementation of 
simultaneous integrated boost techniques may offer the advantage of delivering a higher dose to 
the tumor while maintaining conventional doses to subclinical disease7.
Currently, delineation of esophageal tumors is performed on computed tomography (CT), and 
the added value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been 
explored8-10. Even with FDG-PET/CT fusion, GTV interobserver variability remains high in some 
cases, especially at the cranial and caudal tumor borders11.
On-board online cone beam CT imaging contributed to the development of image guided radiation 
therapy, which improved precision of radiation therapy setup in esophageal cancer12. However, 
cone beam CT offers suboptimal soft-tissue contrast, and imaging of moving organs can be difficult. 
Because of its superior differentiation of soft tissues, integration of magnetic resonance imaging 
(MRI) in radiation therapy is promising13,14. The clinical implementation of MRI before and during 
each fraction of radiation therapy is being explored with the introduction of the Unity MRI-linear 
accelerator (MR-Linac; Elekta AB, Stockholm, Sweden). The MR-Linac combines 1.5 T MRI with a 
state-of-the-art linear accelerator and an online adaptive workflow15,16. Continuous adaptation of 
treatment based on daily MRI scans has the potential to improve radiation precision.
MRI of the esophagus has been improved over the past years. Artefacts in esophageal MRI scans 
from movement of the esophagus have been reduced by technique optimizations, resulting in high-
quality MRI. For instance, positioning a navigator on the diaphragm allows for image acquisition 
in expiration only, thereby reducing motion artefacts17,18. On MRI the individual layers of the 
esophageal wall can be clearly visualized19,20 and a good correlation of T-stage on MRI with 
histopathologic T-stage has been described21. For anatomic visualization and staging of esophageal 
tumors, MRI may even be superior to other imaging strategies22. MRI also provides the opportunity 
to perform functional imaging, such as diffusion-weighted (DW) MRI, a valuable cancer imaging 
biomarker measuring tumor physiology23. DW-MRI depends on the reduction in diffusion within 
the water microenvironment24,25. An increase in cell density, secondary to fast cell proliferation in 
tumors, results in a high signal on DW images. A previous study showed that longitudinal tumor 
lengths of esophageal cancers are more accurately delineated using DW-MRI compared with CT 
or T2-weighted (T2W) MRI only26.
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Delineation studies in other tumor subtypes (eg, head and neck, prostate, and pancreatic cancer) 
already showed promising results regarding delineation of the GTV on MRI27-30. However, 
delineation variation of the GTV in esophageal cancer on MRI compared with FDG-PET/CT is 
unknown.
Because of the increasing interest in integrating MRI into radiation treatment, the aim of this study 
is to evaluate target delineation on T2W-MRI and T2W+DW-MRI compared with current-practice 
FDG-PET/CT.
MATERIALS AND METHODS
Patients
Six patients, diagnosed with locally advanced esophageal cancer between December 2013 and 
December 2014, were prospectively included in a study evaluating response to neoadjuvant 
chemoradiation therapy of esophageal tumors by means of MRI and FDG-PET/CT examinations. 
This study was approved by the local medical ethics committee, and written informed consent 
was obtained from all patients (NCT 02125448). The present study concerns an ancillary study 
evaluating the feasibility of delineation on MRI compared with FDG-PET/CT before the start of 
neoadjuvant chemoradiation. Four patients were male, and 2 were female, with a mean age of 67 
years (range, 54-74 years). We included squamous cell carcinomas (n = 3) and adenocarcinomas 
(n = 3). The patient characteristics are displayed in Table 1. All patients underwent a FDG-PET/
CT scan and endoscopy combined with endoscopic ultrasound (EUS) as standard of care. An 
additional MRI scan was acquired before treatment. After image acquisition, all patients were 
treated with chemoradiation therapy followed by esophagectomy.
Table 1. Baseline characteristics of the 6 esophageal cancer cases
Case cTNM* AJCC location† Histology Male/Female Age (yr)
1 T3N2M0 Upper thoracic SCC M 67
2 T3N1-2M0 Middle thoracic SCC M 54
3 T2N2M0 Lower thoracic, GEJ‡ AC M 71
4 T3N2-3M0 Lower thoracic, GEJ AC F 70
5 T2N0-1M0 Lower thoracic AC M 64
6 T3N1M0 Upper thoracic SCC F 74
Abbreviations: AC = adenocarcinoma; GEJ = gastroesophageal junction; SCC = squamous cell carcinoma.
* Clinical tumor-node-metastasis (cTNM) stage42.
† American Joint Committee on Cancer classification 201242.
‡ Lower thoracic tumor involving the GEJ.
103
2
3
4
6
7
A
1
5
GROSS TUMOR DELINEATION IN ESOPHAGEAL CANCER ON MRI COMPARED WITH 18F-FDG-PET/CT
Image acquisition
FDG-PET/CT
The FDG-PET/CT scan was performed in radiation therapy treatment position on an integrated 
hybrid system combining multidetector CT and FDG-PET (Siemens, Erlangen, Germany). All patients 
were required to fast for at least 6 hours before the injection of 18F-FDG. Blood glucose levels 
were checked in every patient to exclude hyperglycemia. 18F-FDG (2.0 mega- Becquerels/kg) 
was intravenously injected 60 minutes before scanning. A CT scan was performed for attenuation 
correction purposes, and the PET was acquired 3 dimesionally with a scan time of 3 minutes per 
bed position. 18F-FDG-PET/CT reconstruction was performed with ordered-subsets expectation 
maximization for 21 subsets and 4 iterations (Gaussian filter).
MRI
MRI scans were performed on a 1.5 T MRI scanner (Philips Achieva or Ingenia, Best, the 
Netherlands) using TorsoXL (16 channels) or Anterior/Posterior (28 channel) receiver coils. MRI 
scanning consisted of T2W-MRI and DW-MRI in axial planes with a slice thickness of 6.5 mm. 
A respiratory navigator was positioned on the diaphragm to reduce motion artefacts, and scans 
were only acquired in expiration18. The b = 800 s/mm2 images were used for delineation of 
the tumor. Apparent diffusion coefficient (ADC) maps are quantitative measurements of tissue 
diffusivity, calculated over different b-values, and can also be visually displayed24,25. These visual 
displayed ADC maps, calculated from b = 0, b = 200, and b = 800 s/mm2, were available during 
delineation.
Observers
The GTV of the primary tumor of the 6 cases was independently delineated by 10 observers from 
2 centers in the Netherlands. First, they delineated the GTV on fused FDG-PET/CT only. After a 
minimum interval of 2 weeks, delineations of the GTV were repeated on T2W-MRI only. Thereafter, 
DW-MRI of b = 800 s/mm2 and ADC maps were added and delineations were adjusted to create 
a GTV based on a combination of T2W and DW-MRI.
Delineation guidelines
All clinical information of the cases (age, sex, histology, endoscopy report, EUS report, and FDG-
PET/CT report) was provided, reflecting clinical practice. Observers delineated target volumes using 
Volumetool, a software tool developed at the University Medical Center Utrecht, the Netherlands. 
Before the start, 2 consensus meetings were organized to discuss magnetic resonance delineation 
guidelines for esophageal cancer based on the available literature. Gastrointestinal expert 
radiation oncologists, radiologists, and researchers in the field of esophageal cancer imaging 
from the 2 centers participated in these meetings. A digital manual was sent to the observers with 
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the consensus guidelines for delineation on MRI. The observers were instructed to delineate the 
primary tumor GTV and to exclude potential suspicious locoregional lymph nodes on all delineation 
modalities. For delineation on MRI, observers were provided with the FDG-PET/CT report but were 
not allowed to review the noncoregistered PET/CT on a second screen.
FDG-PET/CT delineations
The mean activity in the liver served as the reference for physiologic uptake of FDG in a fasting 
patient31, and a nuclear medicine physician standardized the windowlevel for all cases before 
FDG-PET/CT delineation. Observers were instructed to delineate the tumor on CT and adjust 
delineations after coregistration with FDG-PET. Observers were informed about the slice thickness 
of 3 mm.
T2W-MRI and T2W+DW-MRI delineations
An identical window level and grayscale per patient was preset for the T2W-MRI delineations. 
Observers were informed about the slice thickness of 6.5 mm. After addition of DW-MRI using b 
= 800 s/mm2 images, delineations were adjusted on T2W+DW-MRI. Observers received visually 
displayed ADC maps (calculated from b = 0, b = 200, and b = 800 s/mm2) to determine possible 
T2 shine-through effects, which result in a high signal intensity in the b = 800 s/mm2 image but are 
not related to true diffusion restriction.
Volumetric analysis
The mean and standard deviations (SDs) of the delineated GTVs were calculated per patient and 
compared between FDG-PET/CT, T2W-MRI, and T2W+DW-MRI delineations.
Contour analysis
Overlap analysis
To quantify the overlap among FDG-PET/CT-, T2W-MRI-, and T2W+DW-MRI-based delineations, 
we calculated the generalized conformity index (CIgen), defined as the sum of the common volumes 
between observer pairs divided by the sum of the encompassing volumes between each pair of 
observers. A CIgen of 1 indicates 100% agreement between observers, and a CIgen of 0 indicates 
no overlap in delineation. CIgens were calculated per patient and averaged over all patients per 
modality32.
Delineation variation of the central region: in-slice SD
The central delineated region was defined as the region that was delineated by all 10 observers. 
For this region, a surface distance variation was calculated. A reference contour for each patient 
was computed in 3 dimensions and denoted the median surface GTV33. This median surface, 
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encircling 50% coverage of the GTVs of all observers, was sampled using 8000 equally distributed 
points. For all points, the perpendicular distance to each delineated GTV surface was calculated. 
The variation of the different observers for each point on the median surface was expressed in a 
local observer variation (local SD). For the central delineated region, the overall observer variation 
was calculated for every patient as the quadratic mean of the local SD, demonstrating in slice SD.
Cranial and caudal tumor border variation
The cranial and caudal variation of the esophageal tumor delineations was calculated as the SD of 
the most proximal and distal delineated slice. As a result of the difference in slice thickness between 
FDG-PET/CT (3 mm) and T2W+DW-MRI (6.5 mm), SDs of delineations in the most cranial and 
caudal delineated slice could only be compared between T2W-MRI and T2W+DW-MRI34.
Statistical methods
GTVs and generalized conformity indices were compared using a pairwise t test (paired 2-sided 
Student t test). To compare SDs, the 2-sided F-test was used34. P values lower than .05 were 
considered statistically significant.
RESULTS
Volumetric analysis
The 10 observers delineated significantly smaller absolute GTVs on T2W-MRI and T2W+DW-MRI 
compared with FDG-PET/CT (P = .07 for T2W-MRI vs FDG-PET/CT and P = .01 for T2W+DW-MRI 
vs FDG-PET/CT; Table 2). The FDG-PET/CT-based mean GTVs over all patients was 40.5 cm3 (SD-
per-patient range, 0.8-9.7 cm3). The T2W-MRI-based mean GTV was 34.8 cm3 (SD-per-patient 
range, 1.4-16.1 cm3). On T2W+DW-MRI, the mean GTV decreased to 32.7 cm3 (SD-per-patient 
range, 1.7-8.2 cm3).
Overlap analysis
The mean generalized CIgen over all patients was 0.68 on FDG-PET/CT, 0.66 on T2W-MRI, and 
0.68 on T2W+DW-MRI (Table 2), which was not significantly different across modalities (P = .68 
for FDG-PET/CT vs T2W-MRI; P = .83 for FDG-PET/CT vs T2W+DW-MRI; and P = .26 for T2W-
MRI vs T2W+DW-MRI).
Delineation variation of the central region: in-slice SD
The in-slice SD of the central delineated region was small in the 6 included cases and did not 
differ between modalities (mean, 0.13cm on FDG-PET/CT, 0.10cm on T2W-MRI, and 0.14cm on 
T2W+DW-MRI; Table 2).
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Table 2. Volumetric index and interobserver variation of FDG-PET/CT-, T2W-MRI-, and T2W+DW-
MRI -based GTV delineations
Mean volume (cm³)*
Generalized conformity 
index (CIgen)
Central overall SD
(RMS, cm)†
Case PET/CT T2W-MRI T2W+ DW-MRI
PET/
CT
T2W-
MRI
T2W+ 
DW-MRI PET/CT T2W-MRI
T2W+ 
DW-MRI
1 47.8 ± 7.0 40.6 ± 6.3 38.2 ± 6.1 0.68 0.68 0.72 0.13 0.06 0.07
2 46.3 ± 3.7 32.7 ± 4.2 32.4 ± 4.5 0.75 0.75 0.79 0.13 0.09 0.09
3 75.5 ± 9.7 63.8 ± 8.9 64.6 ± 6.1 0.74 0.74 0.67 0.11 0.14 0.14
4 39.6 ± 8.1 38.0 ±16.1 33.1 ± 8.2 0.62 0.62 0.43 0.20 0.12 0.27
5 22.5 ± 8.6 21.9 ± 3.8 16.4 ± 3.6 0.53 0.53 0.62 0.08 0.08 0.10
6 11.2 ± 0.8 11.7 ± 1.4 11.5 ± 1.7 0.73 0.73 0.71 0.09 0.10 0.09
Mean 40.5 34.8 32.7 0.68 0.68 0.68 0.13 0.10 0.14
Abbreviations; FDG-PET/CT = fluorodeoxyglucose positron emission tomography computed tomography; T2W = T2-
weighted; DW = diffusion-weighted; MRI = magnetic resonance imaging; GTV = gross tumour volume; SD = standard 
deviation; RMS = Root Mean Square, cm = centimetre.
*Mean per patient ± standard deviation. p < 0.05 considered statistically significant, calculated between the means per 
modality, paired-sample T-test (2-tailed).
†Central overall SD = quadratic mean of the local SD weighted for surface (RMS) of the central part of the median surface 
where 100% of the observers agreed delineations.
Cranial and caudal tumor border variation
On all modalities, delineation variability mainly occurred at the cranial and caudal tumor borders. 
SDs in the position of the most cranial and caudal delineated slice are displayed in Table 3, with 
significance levels calculated to report delineation differences between T2W-MRI and T2W+DW-
MRI. Figure 1 visualizes slice variation at the proximal and distal border for delineations on FDG-
PET/CT, T2W-MRI, and T2W+DW-MRI. Case 1 showed large delineation variation at the cranial 
border. In this case, satellite lesions were present cranially of the tumor, which were described in 
the endoscopic report. These lesions were included in the GTV by 4 of 10 physicians on FDG-PET/
CT, T2W-MRI, and DW-MRI. In case 3 and 4 with gastroesophageal junction (GEJ) involvement, 
a significant decrease in caudal border variation was observed on T2W+DW-MRI compared 
with T2W-MRI (P = .04 in case 3, P = .01 in case 4; Table 3). Figure 2 shows an example of GTV 
delineation variation at the GEJ on T2W-MRI (Fig 2a) and T2W+DW-MRI (Fig 2c), displaying 
improved delineation agreement at the caudal border after addition of DW-MRI.
p=0.11
p=0.01
p=0.07
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Table 3. Delineation variation on FDG-PET/CT, T2W-MRI, and T2W+DW-MRI at the cranial and 
caudal tumor borders
Cranial delineation variation 1SD (cm) † Caudal delineation variation 1SD (cm) †
Case PET/CT T2W-MRI T2W+DW-MRI p* PET/CT T2W-MRI p*
1 1.25 1.38 1.30 0.86 0.39 0.57 0.53 0.84
2 0.35 0.21 0.21 1.00 0.20 0.37 0.33 0.78
3 0.09 0.55 0.37 0.25 0.84 0.76 0.37 0.04
4 0.67 1.22 1.00 0.56 0.21 1.22 0.46 0.01
5 1.22 0.44 0.33 0.44 0.57 0.94 0.82 0.69
6 0.20 0.27 0.31 0.69 0.17 0.45 0.53 0.65
Figure 1. Slice variation on FDG-PET/CT, 
T2W-MRI, and T2W+DW-MRI at the cranial 
and caudal tumor borders.
Each block represents a delineated slice. The 
number of observers delineating a slice is 
displayed under the figure. The length of the 
blocks varies according to the slice thickness 
(which was 3 mm on FDG-PET/CT and 6.5 
mm on MRI).
Abbreviations: FDG-PET/CT = 
fluorodeoxyglucose positron emission 
tomography computed tomography;
T2W = T2-weighted; DW = diffusion-
weighted; MRI = magnetic resonance 
imaging. 
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Figure 2. A 71-year-old male patient (case 3) 
with a tumor involving the gastroesophageal 
junction.
a. Delineations of the esophageal GTV of the 
10 observers on T2-weighted MRI only.
b. The added diffusion-weighted MRI scan 
of the same slice, showing the differentiation 
between tumor and gastric wall thickening. 
c. Delineations adjusted after the addition of 
diffusion-weighted MRI.
Abbreviations: GTV = gross tumor volume; 
MRI = magnetic resonance imaging.
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DISCUSSION
This multiobserver study shows that delineation of the primary esophageal tumor on MRI is feasible, 
with interobserver variability for GTV delineation on MRI comparable to that with FDG-PET/CT. 
The main variation is seen at the cranial and caudal tumor border, whereas centrally, differences 
in tumor delineations were small on T2W and T2W+DW-MRI. The addition of DW-MRI to T2W-
MRI in the 2 GEJ-involving tumors significantly reduced the SD of the most caudal delineated slice, 
showing the potential value of DW-MRI for delineation of the caudal border in GEJ-involving cases.
To our knowledge, this is the first study comparing GTV delineation variability on T2W-MRI and 
T2W+DW-MRI to FDG-PET/CT for esophageal cancer. Currently, the gold standard for delineation 
of esophageal cancer is CT (with fused PET if available) and correlation with endoscopy/EUS 
findings. Delineation on CT only is challenging, mainly in differentiating tumor from normal tissue 
at the cranial and caudal tumor borders. Delineation on FDG-PET/CT may help in determining 
these tumor borders; however, FDG uptake does not differentiate between tumor and inflammation, 
which can be difficult especially in tumors involving the GEJ35,36. Furthermore, on FDG-PET/CT 
the target volume can depend on the threshold chosen and may increase or decrease depending 
on the windowing. On the contrary, this study showed promising results for delineation on MRI in 
patients with esophageal cancer. Especially for cases with GEJ involvement, the addition of DW 
imaging to T2W-MRI showed additional value for T2W-MRI only.
In this study, GTVs were significantly smaller on MRI compared with FDG-PET/CT. This may partly 
be caused by the acquisition of MRI at the end of the expiration, whereas for FDG-PET/CT no 
motion-specific scanning techniques were used, showing the extent of malignancy throughout the 
breathing cycle. Furthermore, the finding of a reduced GTV on esophageal MRI is in line with a 
study by Hou et al26. They compared longitudinal length accuracy of esophageal cancer cases 
on T2W-MRI and DW-MRI to CT and found that DW-MRI resulted in the smallest tumor lengths. 
Another study showed a good correlation between DW-MRI tumor lengths and histopathologic 
tumor lengths26. In prostate and cervical cancer, delineations on DW-MRI resulted in slightly smaller 
GTVs compared with histopathology37,38. An important matter is that smaller GTVs may translate 
into smaller clinical target volumes when automatic expansion is used, which theoretically could 
lead to underdosage of microscopic disease. The optimal approach to investigate the accuracy 
of delineation on MRI would be a direct correlation between a preoperative MRI in patients who 
are planned to undergo direct esophagectomy and histopathology. Because patients with locally 
advanced esophageal cancer are treated with neoadjuvant therapy (chemoradiation therapy or 
chemotherapy) before surgery, direct correlation of imaging to pathology cannot be performed. 
An alternative approach is to investigate local control rates, focusing on potential rim recurrences, 
when delineation on MRI is integrated in a magnetic resonance-based workflow.
A limitation of this study is the mean interval of 14 days between FDG-PET/CT and MRI acquisition, 
which limits the comparability between the different modalities in terms of tumor volume in light of 
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potential tumor growth. Therefore, the main focus was the comparison of interobserver variability 
between modalities (demonstrated as CIgens and craniocaudal delineation variation). Second, MRI 
scans were acquired in the axial plane only (with sagittal reconstructions available), and addition 
of sagittal plane imaging of the tumors might further optimize delineation accuracy, especially in 
determining the cranial and caudal tumor extension. Third, the slice thickness of the MRI scans 
was 6.5 mm, and reducing this slice thickness may lead to further improvement in the accuracy in 
GTV delineations. Lastly, the number of patients in this study was limited to 6. Future studies should 
include a larger number of patients to validate our results.
The importance of delineation guidelines in radiation therapy is well known and has been studied 
for CT and FDG-PET/CT in different tumor sites34,39,40. For delineation on MRI, the importance 
of guidelines has been shown for head and neck, pancreatic, and prostate cancer studies27-30. 
Consensus guidelines for esophageal cancer have been developed for CT and FDG-PET/CT 
contouring41. Although GTV delineation was comparable on MRI and FDG-PET/CT, this study 
emphasizes the need to expand clinical experience on magnetic resonance delineation for 
esophageal cancer and to implement robust delineation guidelines. GTVs on MRI were overall 
smaller compared with those on FDG-PET/CT, and the impact on clinical practice is unknown. 
To ensure accurate GTV delineation of the macroscopic tumor and mirror clinical practice, we 
recommend further delineation studies on anatomic T2W-MRI combined with DW-MRI.
Conclusions
MRI-based delineation of the esophageal GTV shows target delineation variability comparable 
to that with FDG-PET/CT, although overall GTVs were smaller on MRI compared with FDG-PET/
CT. The addition of DW-MRI to T2W-MRI potentially facilitates delineation of the caudal border 
in GEJ tumors. Future research should focus on refinement of esophageal MRI acquisition and the 
development of internationally validated delineation guidelines to implement MRI delineation in 
esophageal radiation therapy clinics.
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This thesis aims to investigate the role of DW-MRI in response assessment after neoadjuvant 
chemoradiotherapy (nCRT) of locally advanced oesophageal cancer patients. Trials are ongoing 
which will prove whether organ preservation could be a safe alternative to surgery in patients with 
a clinical complete response. Crucial is the availability of tools that can accurately select those 
patients who will not be harmed by a non-operative treatment. 
Our work has shown that DW-MRI as a single restaging modality after nCRT has a high sensitivity 
of 90-97% for the detection of residual tumour at the expense of a specificity of only 42-57% for 
the assessment of a tumour remnant. With only little experience in interpreting MRI of oesophageal 
cancer, the radiologists interpreting the DW-MRIs probably erred on the ‘safe side’ and overstaged 
rather than understaged in order to avoid undertreatment explaining the low specificity. The first 
studies on the value of DW-MRI for assessment of response to nCRT were in rectal cancer and these 
studies demonstrated specificities of restaging MRI in the same range (35-64%)1,2. A rectal cancer 
study also demonstrated that there is a learning curve of approximately 50 scans3. In rectal cancer, 
the combination of DW-MRI, rectal examination and endoscopy has proven the most accurate 
selection tool to identify patients with a clinical complete response (cCR)2,4.
Several studies focused on endoscopy and EUS for the detection of residual tumour in oesophageal 
cancer and found that 28-55% of patients were incorrectly assessed as having cCR on endoscopy 
and EUS assessment5-8. The low sensitivity on endoscopy and EUS is probably caused by sampling 
error due to difficulties in identifying the right location to biopsy in areas of radiation-induced 
oesophagitis and ulcers. Complete response in the resection specimen did not always present as 
fibrosis at endoscopy and ulceration was not always an indication of residual tumour at histology 
(Chapter 5). Another explanation of the low sensitivity could be the presence of residual tumour cells 
beyond te mucosal wall layer in 28% of the patients9. On EUS the differentiation between tumour, 
fibrosis and inflammation remains challenging as there are no specific differentiating features10. 
An advantage of adding DW-MRI to endoscopy/EUS is the visualisation of the deeper wall layers 
and surrounding tissue as the field of view is substantially larger. Also DW-MRI can differentiate 
between fibrosis and malignancy as fibrosis does not restrict diffusion, while malignancy generally 
does. Chapter 5 found that the addition of DW-MRI to endoscopy and EUS with fine-needle 
aspiration (FNA) indeed led to a higher detection rate of patients with residual tumour, although 
these results should be interpreted with caution as the sample-size of this study was small, with only 
a limited amount of patients with pathological complete response (pCR). This was the first study on 
this subject and the promising results call for further research. 
MRI of oesophageal cancer is promising but some challenges in the MR protocol need to be 
addressed. One challenge with DW-MRI is cardiac motion for tumours in the middle and distal 
oesophagus, gastric motion for tumours located in the distal oesophagus/gastro-oesophageal 
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junction and breathing motion for all oesophageal tumours. The use of an anti-peristaltic agent 
(e.g. scopolamine-N-butyl bromide) has been reported by some to be beneficial for reduction of 
the movement of the gastric wall during scan acquisition11,12. Gastro-oesophageal junction tumours 
pose a challenge as some patients with pCR show false-positive hyperintense foci on DW-MRI. This 
may be explained by the fact that collapsed normal stomach wall also can show hyperintensities on 
DW-MRI probably due to fluid ‘trapped’ in the folds. The administration of a negative oral contrast 
agent, for instance pineapple juice, is currently used for the visualisation of gastric cancer on MRI 
to suppress signal from physiologic stomach filling and might also improve imaging of gastro-
oesophageal junction tumours11,13,14. 
Also, the optimal timeframe for response evaluation is yet unknown. Because the standard timing 
of surgery is 6-8 weeks after completion of nCRT15, the studies in this thesis generally performed 
response assessment 4-6 weeks after completion of nCRT. The DW-MRI in some patients may 
be ‘false positive’ at this early time point due to postradiation inflammation or, as has been 
observed in rectal cancer, tumours keep regressing with time until some eventually even completely 
disappear16,17. The ‘test of time’, i.e. a prolonged interval between completion of nCRT and response 
assessment, could be a good approach to solve confounding signals on DW-MRI. One could argue 
that false positive hyperintensities on DWI caused by postradiation inflammation may disappear 
and some tumours might have completely regressed. A nationwide analysis in the Netherlands 
showed that a prolonged interval ( ≥10 weeks for adenocarcinomas and ≥13 weeks for squamous 
cell carcinomas) between nCRT and surgery indeed increased the pCR rates18. Another advantage 
of the ‘test of time’ is the selection of patients with biologically aggressive tumours, that metastasize 
early. In 8% of the patients distant metastases are currently detected on FDG-PET/CT before 
oesophagectomy19,20. In patients having distant metastases, avoiding a futile surgical procedure 
with considerable associated morbidity may be desirable. 
To date, FDG-PET/CT is the main modality for distant staging of oesophageal cancer. However, 
new imaging modalities such as whole-body DWI are rapidly evolving21-23. Previous studies 
have already demonstrated that DW-MRI is superior to FDG-PET/CT for the detection of liver 
metastases24,25. In oesophageal cancer a similar accuracy of whole-body DWI compared to FDG-
PET/CT was reported22. In Chapter 4 DW-MRI and FDG-PET/CT were compared for locoregional 
response assessment after nCRT. The 92-96% sensitivity for detecting residual oesophageal tumour 
after nCRT on DW-MRI was superior to the 69% of PET/CT. The low sensitivity of FDG-PET/CT may 
be explained by the difficulty of detecting glucose uptake on FDG-PET/CT in scattered residual 
tumour. Also, in areas of radiation oesophagitis one may understage tumour residue whereas DW-
MRI seems to suffer less heavily from inflammatory response. The accuracy of detecting lymph node 
metastases with DW-MRI (sensitivity 58%-67%; specificity 86%) was comparable with FDG-PET/
CT (sensitivity 50%-42%; specificity 81%-86%). This was quite surprising as our hypothesis was 
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that the differentiation between benign and malignant lymph nodes on DW-MRI would be more 
challenging than on FDG-PET/CT, as diffusion restriction is seen in both benign and malignant 
lymph nodes. Also, on MRI the field of view (FOV) is limited to the area around the oesophageal 
tumour whereas FDG-PET/CT visualises the whole mediastinal area. The high specificities on DW-
MRI suggest that the absence of suspect lymph nodes may yield predictive value for absence of 
nodal disease at histopathology. Previous literature about restaging of lymph nodes after nCRT on 
DW-MRI is scarce, but Riddell et al. compared N-staging on MRI to the surgical specimen and 
found a sensitivity of 64% and specificity of 79%26. Although these results seem promising, for 
future studies a FOV of DW-MRI containing the complete mediastinal area is essential for accurate 
N-staging. If it can be confirmed that DW-MRI is not inferior to FDG-PET/CT for locoregional and 
distant staging, whole-body DWI could potentially serve as a one stop shop imaging modality.
Meanwhile, the MR linear accelerator (MR-Linac) has entered clinical practice and MR guided 
radiotherapy treatment is increasingly explored for its potential advantages, such as reduced 
margins and plan adaptation which could reduce morbidity and increase treatment efficacy27,28. 
A considerable decrease in tumour volume was observed in oesophageal cancer patients during 
chemoradiotherapy treatment29. In Chapter 6 we found that delineation of the radiotherapy target 
region on DW-MRI is feasible. Plan adaptation and radiation dose escalation on the MR-Linac may 
increase the amount of complete responders. This is especially true for squamous cell carcinomas 
which are known to be more radiosensitive than adenocarcinomas6. A randomized-controlled 
multicenter study compared definitive chemoradiotherapy of 61.6 Gray to the standard 50.4 Gray 
and found no increased local control nor better overall survival30. However, future studies should 
explore if dose escalation in patients with predicted good response to nCRT results in an increase 
of complete responders. To select patients with a high chance of achieving a complete response the 
relative difference in apparent diffusion coefficient (ADC) derived from DW-MRI before vs. during 
nCRT as shown in Chapter 3 as well as circulating tumour DNA (ctDNA) may be useful31-34. These 
biomarkers and especially their integration should be the subject of future studies. 
The introduction of neoadjuvant chemoradiotherapy for patients with locally advanced oesophageal 
cancer has led to new diagnostic challenges. A point of discussion is whether a select group of 
patients with complete response after chemoradiotherapy could be deferred from surgery. Careful 
selection of patients for watchful waiting is crucial. The research presented in this thesis found 
promising results for DW-MRI as part of a multimodality response assessment approach. DW-
MRI added accuracy to the restaging of oesophageal cancer by endoscopy/EUS examination 
and for both local tumour and regional nodal restaging DW-MRI competes with FDG-PET/CT. 
The promising outcomes of the studies reported in this thesis contributed to the initiation of the 
multicentre PRIDE study, which is currently exploring the role of MRI, FDG-PET/CT, ctDNA and 
endoscopy/EUS in response prediction and assessment of oesophageal cancer35. At the same 
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time, the Dutch SANO trial36 and the French ESOSTRATE trial37 are comparing a watch-and-wait 
approach to surgery for clinical complete responders after neoadjuvant chemoradiotherapy. In 
the coming years, future studies should further investigate which is the most accurate combination 
of modalities for selection of clinical complete responders, what would be the optimal timing 
of response assessment and which would be the most cost-efficient follow-up schedule to move 
forward the paradigm shift towards watchful waiting in oesophageal cancer therapy.
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Locally advanced oesophageal cancer patients are currently treated by chemoradiotherapy 
followed by surgery. In 29% of the patients, no residual cancer cells are detected in the resected 
specimen. These patients are called ‘complete responders’. Accurate response assessment after 
chemoradiotherapy is likely to impact clinical decision making, as many experts state that patients 
with a clinical complete response could be deferred from surgery. The aim of this thesis was to 
investigate whether diffusion-weighted MRI (DW-MRI) is able to improve the clinical selection after 
chemoradiotherapy of patients who are eligible for organ preservation. Also, the potential for MRI 
in radiotherapy treatment planning was investigated.
The visual response assessment on DW-MRI by three oncologically specialised radiologists in 51 
patients was explored in Chapter 2. A high sensitivity for the detection of residual tumour was 
found, implicating a low risk of missing complete responders. At the same time, the specificity was 
low, which means that the risk of overstaging a patient with a complete response was considerable. 
Thus with subjective response evaluation, radiologists tended to err on the “safe side” and rather 
overstaged than understaged the primary oesophageal tumour after chemoradiotherapy.
From DW-MRI the apparent diffusion coefficient (ADC) can be calculated. The ADC is a 
quantitative, and thereby potentially objective, measurement of the diffusivity of water molecules in 
tissues. In Chapter 3 the value of quantitative DW-MRI was explored by performing a systematic 
review. Fourteen studies comprising 516 patients calculated the ADC before, during and after 
chemoradiotherapy. It was found that the relative increase in ADC (delta ADC) during, compared 
to before chemoradiotherapy, can potentially differentiate between good and poor responders. For 
response assessment after chemoradiotherapy, ADC values seem inadequate because the region of 
interest size and placement is hampered by small or absent tumour in good/complete responders. 
Therefore, response after chemoradiotherapy may rather be assessed visually.
Another widely used cancer imaging technique is computed tomography combined with 
18F-fluorodeoxyglucose positron emission tomography (FDG-PET/CT). Although FDG-PET/CT is 
used for the staging of distant metastases and lymph nodes in oesophageal cancer, it is also 
increasingly explored for its role in local restaging after chemoradiotherapy. Chapter 4 compared 
DW-MRI to FDG-PET/CT for this purpose in 33 patients and it was found that MRI resulted in a 
more accurate response assessment as compared to FDG-PET/CT. The most important finding was 
the higher sensitivity on DW-MRI as compared to FDG-PET/CT.
If DW-MRI can become the main imaging modality in response assessment of oesophageal cancer 
after chemoradiotherapy, it is important to understand its potential benefit to endoscopy and 
endoscopic ultrasound (EUS). Previous studies found that a considerable proportion of residual 
tumours is currently missed based on the biopsies and aspirates taken by endoscopy and EUS. 
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In Chapter 5 the addition of DW-MRI to endoscopy/EUS with fine needle aspiration (FNA) led 
to a higher detection rate of patients with residual tumour in 22 patients. It was also found that 
the clinical perception of the gastroenterologist did not add to the pathological assessment of 
biopsies: complete response neither always presented as residual fibrosis, nor did ulceration 
always implicate residual tumour at 4 to 6 weeks after chemoradiotherapy.
 
Simultaneously, the development of an MRI-scanner with linear accelerator for radiotherapy has 
led to the possibility of MRI guidance of radiotherapy. Potential advantages of MRI guidance are 
reduced margins, plan adaptation and reducing the fractions of radiotherapy. In Chapter 6, ten 
observers delineated the radiotherapy target region of the primary oesophageal tumour in six 
patients on DW-MRI, using FDG-PET/CT as the reference standard. Delineation on DW-MRI was 
feasible with interobserver variability comparable to that of FDG-PET/CT.
To conclude, by exploring the role of DW-MRI in a multimodal approach, this thesis contributes to 
the movement towards organ saving treatment for locally advanced oesophageal cancer patients 
with a clinical complete response to chemoradiotherapy. 
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Patiënten met lokaal gevorderde slokdarmkanker worden op dit moment behandeld met 
chemoradiatie gevolgd door een operatie. Na de operatie vindt de patholoog in 29% van de 
patiënten geen tumorcellen meer in de slokdarm, dit wordt ook wel een ‘complete respons’ 
genoemd. Bij deze patiënten wordt overwogen om de chirurgie na chemoradiatie achterwege te 
laten: orgaansparende behandeling. Om te bepalen wie in aanmerking komt voor orgaansparende 
behandeling na chemoradiatie is een goede selectiemethode belangrijk.
Technologische ontwikkelingen hebben ervoor gezorgd dat het mogelijk is om goede afbeeldingen 
van de slokdarm te maken met magnetic resonance imaging (MRI). MRI biedt tevens de mogelijkheid 
om functionele beeldvorming, zoals diffusie-gewogen MRI, te combineren met anatomische 
beelden (DW-MRI). In dit proefschrift wordt onderzocht of DW-MRI de selectie van patiënten voor 
orgaansparende behandeling na chemoradiatie kan verbeteren en of het veilig is om DW-MRI 
voor het bestralingsplan van slokdarmkanker te gebruiken.
In Hoofdstuk 2 wordt de aanwezigheid van tumor op DW-MRI na chemoradiatie onderzocht 
door 3 onafhankelijke radiologen in 51 patiënten. Er werd een hoge sensitiviteit voor de detectie 
van residuele tumoren gevonden, wat betekent dat er een laag risico was om residuele tumoren 
te missen. Tegelijkertijd was de specificiteit laag, dus er was wel een relatief grote kans op het 
overstadieren van complete respons.
Vanuit de DW-MRI kun je een kwantitatieve waarde berekenen: de apparent diffusion coefficient 
(ADC). Dit is een objectieve parameter voor de diffusie van watermoleculen in weefsels. In 
Hoofdstuk 3 wordt de waarde van ADC onderzocht in een systematisch literatuuronderzoek. 
Veertien artikelen met 516 patiënten werden geïncludeerd. De relatieve stijging van ADC (delta 
ADC) tijdens chemoradiatie vergeleken met vóór start van chemoradiatie lijkt onderscheid te 
kunnen maken tussen goede en slechte responders. Voor de waarde van ADC voor restadiëring 
na neo-adjuvante chemoradiatie, liepen de resultaten uiteen. Dit komt waarschijnlijk doordat het 
moeilijk is om te bepalen in welk gebied de ADC-meting gedaan moet worden als een slokdarm 
geen, of bijna geen, residueel tumorgebied meer heeft.
Voor het bestralingsplan wordt gebruik gemaakt van 18F-fluorodeoxyglucose positron emission 
tomography – computed tomography (18F-FDG-PET/CT) om de precieze locatie en vorm van de 
tumor in te tekenen. Ook wordt FDG-PET/CT in steeds grotere mate onderzocht voor de selectie 
van complete responders na chemoradiatie. In Hoofdstuk 4 worden DW-MRI en FDG-PET/CT 
vergeleken voor de lokale restadiëring van de slokdarmtumor in 33 patiënten. DW-MRI resulteerde 
in een betere responsbeoordeling vergeleken met FDG-PET/CT, waarbij voornamelijk de sensitiviteit 
op DW-MRI hoger was dan op de FDG-PET/CT.
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Met behulp van een endoscoop kan de maag-darm-lever arts (MDL-arts) de slokdarm beoordelen 
en biopten afnemen. De endoscopische echo (EUS) kan hieraan worden toegevoegd: middels echo 
wordt vanuit het lumen van de slokdarm door de wand van de slokdarm heen gekeken. Met behulp 
van EUS kunnen aanvullend puncties van lymfeklieren genomen worden. Eerdere onderzoeken 
suggereren dat er met endoscopie/EUS na chemoradiatie een hoge kans is op vals-negatieven. 
Indien dit gebruikt wordt voor de selectie van complete responders, zouden patiënten met residu 
tumor mogelijk onterecht worden onthouden van de operatie. In Hoofdstuk 5 werd de aanvullende 
waarde van DW-MRI bij endoscopie/EUS na chemoradiatie onderzocht in 22 patiënten. Alle 
patiënten ondergingen een MRI-scan en endoscopie/EUS onderzoek vóór en na chemoradiatie. 
De aanvullende beoordeling van de radioloog op DW-MRI aan de biopten en puncties van 
endoscopie/EUS leidde tot een hogere detectie van patiënten met residuele tumor. Daarnaast bleek 
het lastig voor de MDL-arts om een klinische inschatting te maken van de verdenking op residuele 
tumor op basis van visuele beoordeling tijdens het endoscopie/EUS-onderzoek.
Tegelijkertijd heeft de ontwikkeling van een MRI met lineaire versneller voor radiotherapie 
geleid tot de mogelijkheid van MRI-begeleiding tijdens de bestraling. Mogelijke voordelen 
van MRI-begeleiding zijn verminderde marges, directe aanpassing van het bestralingsplan en 
het verminderen van de fracties van radiotherapie. Omdat MRI op dit moment nog niet wordt 
gebruikt voor het bestralingsplan van slokdarmkanker is het allereerst belangrijk om te kijken of 
het veilig zou zijn om MRI te gebruiken voor het intekenen van slokdarmkanker (Hoofdstuk 6). Tien 
artsen hebben de slokdarmtumor ingetekend op PET-CT en op MRI en er werd een vergelijkbare 
interobserver-variatie voor beide modaliteiten gevonden. Hoewel verder onderzoek in een grotere 
groep nodig is, waren de resultaten veelbelovend.
Concluderend werd in dit proefschrift de rol van DW-MRI onderzocht voor de selectie van patiënten 
die een orgaansparende behandeling zouden kunnen ondergaan na chemoradiatie. Daarmee 
draagt dit proefschrift bij aan de ontwikkeling van orgaansparende behandeling voor patiënten 
met slokdarmkanker en een complete respons na chemoradiatie. 
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In this chapter, the thesis will be analysed in the perspective of the valorisation focusing on its 
relevance for society and clinics. Also, the novelty and future realisation will be outlined. The 
following five aspects will be discussed:
1. Socio-economic relevance
2. Target audience
3. Products
4. Innovative value
5. Realisation
Socio-economic relevance
Cancer has a major impact on society across the world and oesophageal cancer is in the top ten 
of most common cancer types worldwide. Especially the incidence of adenocarcinomas in men 
is growing rapidly. One of the major risk factors for oesophageal adenocarcinomas is gastro-
oesophageal reflux disease (GORD) causing metaplasia of the distal oesophagus. Obese or 
overweight individuals are significantly more at risk of suffering from GORD. In 2016, 39% men 
and 39% women aged 18+ were overweight (BMI >25 kg/m2) and 11% of men and 15% of 
women were obese (BMI>30kg/m2).
Patients diagnosed with locally advanced oesophageal cancer are currently treated by neoadjuvant 
chemoradiotherapy followed by surgery in the Netherlands. A personalised treatment approach is 
increasingly explored in many cancer types and could also be interesting for oesophageal cancer 
patients. Previous analyses showed that in almost 30% of the patients no residual cancer cells were 
found in the surgical specimen, a phenomenon which is called a “pathological complete response”. 
These patients might benefit from an organ saving treatment approach after ‘neoadjuvant’ 
chemoradiotherapy. This thesis outlines the role for MRI in a multimodal diagnostic approach after 
chemoradiotherapy to open the door to organ preservation for clinical complete responders. Also, 
the feasibility for MRI was investigated at the start of treatment for the delineation of the target 
volume. 
Target population
Following national guidelines, patients with oesophageal cancer are currently treated by 
chemoradiotherapy followed by surgery. This thesis investigates a multimodal diagnostic approach 
to select patients for organ preserving treatment after chemoradiotherapy. Therefore, the results 
of this thesis may primarily impact the treatment plan of oesophageal cancer patients. Omitting 
surgery may likely impact their lives because oesophageal surgery is reported to have a major 
impact on patients’ quality of life. Interestingly, a study in rectal cancer reported promising 
improvement of the quality of life after chemoradiotherapy in the watch-and-wait group compared 
with the surgery group. If surgery is to be omitted in oesophageal cancer patients with a clinical 
complete response after chemoradiotherapy, future studies should explore the quality of life as well 
5
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as the cost efficiency of this new treatment.
The results in this thesis may also impact the work of the multidisciplinary team of oesophageal 
cancer patients. The assessment of MRI by the radiologist will probably play a prominent role in the 
response assessment after chemoradiotherapy. Furthermore, implementing an organ preserving 
treatment approach may impact the numbers of performed operations, while this number is 
currently an important requirement for quality assessment in the Netherlands.
Products
There are no new products that have been developed with the results of this thesis.
Innovative value
An organ-preserving treatment approach is upcoming in other cancer sites and the promising 
response rates to chemoradiotherapy opens the debate for oesophageal cancer patients. To select 
the right patients for organ preservation, accurate response assessment is essential. The high 
rates of false negative biopsies taken by endoscopy stresses the need for an accurate additional 
imaging tool. MRI is increasingly explored for this purpose because of the good visualisation of soft 
tissues combined with functional diffusion-weighted imaging. This thesis reports new and relevant 
studies on the clinical assessment on MRI in oesophageal cancer and thereby contributes to the 
development of a personalised treatment approach for oesophageal cancer patients.
Realisation
Currently, the multicentre PRIDE trial is exploring the combination of MRI, FDG-PET/CT, endoscopy/
EUS and circulating tumour DNA for predicting and assessing the response to chemoradiotherapy 
in oesophageal cancer. At the same time, two trials are exploring a watch-and-wait approach 
for patients with oesophageal cancer: the SANO trial in the Netherlands and the ESOSTRATE 
trial in France. The combination of the aforementioned studies will undoubtedly lead to a more 
personalised treatment approach for patients with locally advanced oesophageal cancer.
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En dan nu eindelijk het hoofdstuk dat door iedereen gelezen wordt.
Allereerst heel veel dank aan alle patiënten. Ik bewonder jullie bereidheid om meermaals vrijwillig 
naar het AvL te komen om in het lawaai van een MRI-scanner te gaan liggen en zelfs een extra 
endoscopie/EUS-onderzoek te ondergaan, puur om de patiënten ‘na jullie’ te kunnen helpen. 
De resultaten van deze onderzoeken helpen onze kennis over slokdarmkanker verder en jullie 
nuchtere instelling heeft mij ook persoonlijk gemotiveerd.
Mijn promotor, prof. dr. Beets-Tan, beste Regina, je enthousiasme voor de wetenschap en 
vertrouwen in de toekomst van de radiologie in een multidisciplinaire setting is inspirerend. Door 
je ervaring met de watch-and-wait voor patiënten met rectumcarcinoom kregen mijn projecten in 
sneltreinvaart richting. Dank voor je vertrouwen in mij.
Copromotoren, dr. Bartels-Rutten en dr. Voncken, lieve Annemarieke en Francine, steunpilaren, 
zonder jullie enthousiasme was dit proefschrift er niet geweest. Onze wekelijkse gezellige 
vrijdagmiddag overleggen en jullie 24/7 bereikbaarheid hebben mij hierheen gebracht. Ik vind 
het knap hoe jullie de kliniek combineren met de wetenschap en ook nog een lief gezin. Dank 
voor jullie vertrouwen en de vrijheid die jullie me hebben gegeven om overal ter wereld aan mijn 
artikelen te kunnen werken. Ik heb ontzettend veel van jullie geleerd en jullie zijn voor mij allebei 
een groot voorbeeld.
Prof. dr. Masclee, Prof. dr. Bouvy, Prof. dr. Haustermans, Prof. dr. Stassen en Prof. dr. Stoker, 
hartelijk dank voor het beoordelen van mijn proefschrift. Prof dr. Wijnhoven, het is een eer dat u 
wilt plaatsnemen in de oppositie, ik heb veel van u en uw onderzoeksgroep geleerd de afgelopen 
jaren en kijk uit naar mijn verdediging.
Slokdarm-maag-team van het AvL, dank voor de gezellige tijd en jullie kritische blik. Jullie hebben 
mijn presentaties op congressen tot een hoger niveau getild. Dr. van Dieren, lieve Jolanda, dank 
voor de gezellige dagen op de scopiekamer. Van goudmarkers tot bite-on-bite biopten en CRFs, 
geen enkel idee is jou te gek. Dr. van Sandick, lieve Johanna, dank voor je hulp bij mijn onderzoek 
en manuscripten, en natuurlijk ook voor de hulp bij mijn sollicitatie voor de chirurgie in het OLVG. 
Dr. Aleman, Berthe, dank voor je heldere blik op alle manuscripten en op mijn ontwikkeling vanuit 
de OOA-commissie. Dr. Hartemink, beste Koen, dank dat je plaats nam in mijn OOA-commissie 
en voor je betrokkenheid bij het onderzoek. Yvonne, je bent een grote aanwinst voor de patiënten 
maar ook voor het team. Ik vond het altijd heel leuk om met je te werken, dankjewel. Willem, 
immer collega, dank voor de gezellige samenwerking in het onderzoek en nu ook in de kliniek, 
“we moeten de buik in”! RTstudieondersteuners, clinical project managers en MRI-laboranten, dank 
voor de planning en organisatie.
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Beste mede-auteurs. Collega’s uit UMC Utrecht, dank voor de samenwerking. Dr. Lambregts en 
dr. Maas, Doenja en Monique, veel dank voor jullie tijd bij het scoren van de MRI-scans en in 
het bijzonder voor jullie advies vanuit jullie ervaring bij het rectumcarcinoom. Dr. Nowee, beste 
Marlies, dank voor de samenwerking bij ons MR-intekenstuk. Dr. Ir. ter Beek, beste Leon, hartelijk 
dank voor je enthousiaste hulp bij de ontwikkeling van perfecte MRI-protocollen en de vele test-
avonden. Dr. Ir. Bartels, Wilbert, dank voor de leerzame MRI-cursus in Utrecht en voor je werk bij 
onze systematic review. Ook al is het geen ‘original’, ben ik misschien wel het meest trots op de 
manier waarop we de literatuur omtrent ADC in slokdarmcarcinoom hebben ontleed.
Lieve Paranimfen, classic, op moment van schrijven zijn jullie nog niet gevraagd dus hopelijk 
zeggen jullie ja... Philippe, volgens mij weten we inmiddels evenveel van slokdarmkanker want je 
hebt jarenlang naar mijn verhalen geluisterd. Geneeskunde hadden we bijna samen op Hawaii 
gedaan omdat daar geen loting was, maar gelukkig konden we alsnog op co-schap kitesurfen op 
Aruba gevolgd door een co-schap no-stress jungletrips in Suriname. Zelfs ons eigen bedrijf in een 
andere ‘branche’ blijkt ineens een succes en samen een marathon rennen was eigenlijk niet een 
zwaar maar gewoon gezellig. Ik ben heel blij met jou als beste vriend. Brigit, op 23 oktober 2020 
deed jij het voor, vanzelfsprekend heb je de lat op het dak gelegd. Toen je het tuinhuis binnenkwam 
wist ik meteen dat jij bij ons op de kamer moest komen. Je doorzettingsvermogen is aanstekelijk en 
we zaten altijd op 1 lijn. Je bent een loyale en lieve vriendin en een soort zus geworden door de 
jaren heen. Met jullie naast me kan er niks misgaan, op naar nog vele jaren vriendschap.
Dank aan alle onderzoekers uit het tuinhuis en het O-gebouw, die er tijdens de PhD retreat met 
“onze” DJ in Zeeland tot aan een wild weekend Antwerpen een mooie promotietijd van hebben 
gemaakt. Jorrita, de spil in het web van het tuinhuis, dankjewel. Marit, het was fijn om samen 
brainstormen over de overeenkomsten en verschillen tussen het rectum en de oesophagus onder 
het genot van cappuccino en (halve) gevulde koeken, dank voor de waardevolle vriendschap. 
Myrte, kort maar krachtig was onze tijd in het AvL en ik heb genoten van de bakken energie die 
jij altijd meebracht. Lisa, dank voor de gezellige tijd, voor je interesse in mijn onderzoek en voor 
de steun op ons allereerste ECR. Het weekend carnaval in Maastricht met de blondies zal ik nooit 
vergeten. Maurits, met jou een biertje drinken of op congres en alle zorgen verdwijnen. Dank voor 
je rust en intelligentie, je bent een trouwe vriend. Femke, spring in ’t veld, dank voor je vrolijkheid 
en betrokkenheid. Rebecca, ik heb genoten van de gezelligheid tijdens ESGAR in Dublin samen.
Collega’s, chirurgen en verpleegkundigen in het OLVG Oost, dank voor de kans om in zo een 
warm stadsziekenhuis de kliniek in te gaan en voor de gezelligheid tijdens alle diensten. Dank ook 
voor jullie steun en betrokkenheid bij mijn carrière, ik weet zeker dat we elkaar in de toekomst nog 
tegenkomen.
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Vrienden van Maarssen tot Utrecht, Leiden, Rotterdam en natuurlijk door heel Amsterdam, dank voor 
de waardevolle vriendschappen. Nadine, ik ken je al sinds mijn geboorte, altijd trouw en eerlijk, 
dank voor je humor en je interesse in alles wat ik doe. Emma, dank voor de bijzondere vriendschap 
die zelfs in stand bleef toen we nog maar in groep 4 zaten en jij naar Groningen verhuisde. Lisa en 
Boudewijn, de E&M’ers die mij motiveerden om op de beste school van Nederland te blijven en nu 
zijn jullie vlammende advocaten van hier tot NYC. Dank voor de vele grote feesten, voor de slappe 
lach en de mooie vriendschap door dik en dun. Anna, vriendinnen sinds we samen de dakgoot 
schoonmaakten, dank voor je eerlijkheid, met jou is het altijd vertrouwd. Florine, dank voor je 
vastberaden interesse, steun en toeverlaat, als huisgenoot en nu ook vanuit Rotterdam, de stad met 
brede stoepen. Sophie-5, Charissa, Vivian en Doortje, jullie zijn unieke vriendinnen en we zullen 
dineren tot en met ons pensioen. Janine, Caro en Laura, dank voor de eiland-vriendschap van 
Aruba tot Wangerooge tot Ameland, snel weer surfen of op een steen zitten als dit boek gedrukt is. 
Lieve Wilma en Emile, dank voor jullie support. Wilma stuurde de vacature en nu is het afgerond, 
vanzelfsprekend in Hermès oranje.
Lieve schoonfamilie, Betty, Elka, Paul, Marischka, Kiki en Maarten, dank voor alle gezellige 
avonden, uitjes, goede gesprekken en de prachtige reizen. Veel dank ook voor jullie interesse in 
mijn onderzoek, carrière en eindeloze hobby’s.
Lieve familie, oma Tini, dank voor de gezellige etentjes in Amstelveen en voor je scherpe blik. Deze 
oma kun je niet voor de gek houden, dit is de slimste van Nederland. Opa Johan en oma Lies, 
dank voor de warmte van de grote gezellige familie in Bergen. Lieve papa en mama, dank voor 
alles. Ik ben heel blij dat jullie me overal in steunen met als enige advies om zelf na te denken en 
met beide benen op de grond blijven staan. Het huis staat altijd open voor zoete inval en met de 
hondjes erbij is het feest compleet. Marc en Charlotte, dank voor jullie eerlijke adviezen. Marc, 
vlak voordat ik aan mijn promotie begon, zocht ik je op op Bali waar je met passie een hele 
specerijenfabriek optimaliseerde. Ik was echt onder de indruk van hoe snel je Indonesisch sprak en 
hoe geliefd je was onder alle fabrieksmedewerkers. En Charlotte, je bent lief en (eigen)wijs, dank 
voor je heldere blik en voor je keiharde lachbuien met de tranen in je ogen. Het was te gek om 
door mijn kleine zusje door het grote Toronto geleid te worden en ik kan niet wachten om samen 
te dokteren. Michiel, dank voor je vrolijkheid, energie en loyaliteit.
Achter elke succesvolle vrouw staat een man die tonijnburgers bakt. “Ik wíst al dat ze je zouden 
aannemen” waren je woorden nadat ik was aangenomen en waarschijnlijk zeg je vandaag “Ik 
wíst al dat het je zou lukken”. Allerliefste Matthijs, top 1. Dank voor je adviezen die dit proefschrift 
perfect hebben gemaakt en voor je onvoorwaardelijke steun. Je geeft me het vertrouwen dat niks 
onmogelijk is.
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